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Thursday, 3rd October 2013
Session 1 Interventional Cardiology
Chair: Prof. David Foley
18.30–21.00 Case Reviews
Session 2 Electrophysiology




08.55–09.00 Welcome from Dr Donal Murray, President
Session 3 Imaging
Chair: Dr Caroline Daly
09.00–09.30 Can we improve post - MI cardiac remodeling using fish oil? A randomized control trial using cardiac magnetic
resonance imaging
Prof Raymond Kwong
Brigham & Women’s Hospital, Boston
09.30–10.30 Oral Presentations
1. One Year Follow Up of the CAPP Study: A Randomised Controlled Trial Comparing EST to Cardiac CT
McKavanagh P, Lusk L, Ball PA, Trinick TR, Duly E, Verghis RM, Agus AM, Walls GM, McCusker S, Orr C, Hamilton A,
Harbinson MT, Donnelly PM
Ulster Hospital, Dundonald, Belfast, NI
2. Prevalence of Cardiac Abnormalities in the Turner Syndrome Population in Northern Ireland
Noad RL, McManus J, McKeown PP, Muir AR
Belfast Health and Social Care Trust, NI
3. Clinical Application of Perfusion CMR in Assessment of Suspected Coronary Artery Disease
James S, Waterhouse DF, Barrett M, Murphy TM, McAdam B, Foley DF, Sheahan RS, O’Hanlon R
Centre of Cardiovascular Magnetic Resonance, Blackrock Clinic, Dublin, Ireland
4. Hypertrophic Cardiomyopathy: Clinical and Imaging Characteristics of an Irish HCM Registry
McClelland S, O’Connor SA, Donohue S, Lavelle L, McErlean A, Dodd J, O’Hanlon R, Meaney J, McCreery CJ, Clarke J,
McDonald K, Quinn M, Erwin JE, Quigley PJ, Maurer BJ, Keane D
St. Vincent’s University Hospital, Dublin, Ireland
5. T1 Mapping Detects Myocardial Oedema in a Rat Model of Myocardial Ischaemia
O h-Ici D, Jeuthe S, Kozerke S, Kuehne T, Berger F, Messroghli D
German Heart Institute, Berlin; King’s College, London, UK; University and ETH Zurich, Switzerland
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6. Clinical Outcomes of Patients with Low-Flow, Low Gradient Severe Aortic Stenosis and Either Preserved or Reduced
Ejection Fraction Undergoing TAVR
*O’Sullivan CJ, *Stortecky S, Heg D, *Pilgrim T, *Hosek N, *Zanchin T, *Meier B, *Windecker S, *Wenaweser P
*Swiss Cardiovascular Centre, Bern University Hospital; Clinical Trials Unit, Bern University Hospital, Switzerland
10.30–11.00 Poster Presentation
Exhibition/Coffee
7. In-Vivo Study of Myocardial Metabolic Changes in a Rat Model
O h-Ici D, Weiss K, Sigfridsson A, Wissman L, Busch J, Messroghli D, Kozerke S
German Heart Institute, Berlin; King’s College, London, UK; University and ETH Zurich, Switzerland
8. Significant Radiation Dose Reductions in Advanced Cardiac CT Imaging—Are We Keeping Up with the Guidelines? Our
Experience with Ireland’s Only 320 Slice
Kindler H, King G, Clarke J
Eagle Lodge Cardiac Centre, Limerick, Ireland
9. Exposure to Ionizing Radiation when Monitoring for Chemotherapy-Related Cardiotoxicity Using Multigated Acquisition
Scanning: Does It All Add Up?
Murtagh G, Addetia K, Yu Z, DeCara J
University of Chicago, Chicago, Illinois, USA
10. Increased Anteroseptal Wall Thickness in HIV Positive Males Compared to Healthy Male Controls
Morgan RB, Loy A, O’Dea S, Mulcahy F, Meaney J, Daly CA
St James’s Hospital Dublin, CAMI St James’s Hospital, Dublin, Ireland
11. Serum Amyloid P-Component Update: Potential Mechanism by Which SAP Attenuates LV Remodelling in Hypertensive
Heart Disease
Horgan S, Watson C, Glezeva N, Neary R, Ledwidge M, McDonald K, Baugh J
Conway Institute, University College Dublin, Dublin, Ireland
12. Adverse Impact of Smoking on Mortality and Kidney Transplantation Among Patients with and without Cardiovascular
Disease in End Stage Kidney Disease
Roche D, Lim RY, Yermak D, Casserly L, Cronin C, Hannigan A, Kiernan T, Stack A
University Hospital Limerick, Limerick, Ireland
13. Renal Artery Sympathetic Nerve Anatomy in The Human: A Histologic Post-Mortem Study to Guide Future Catheter
Denervation Strategies
Roy AK, Cunningham M, Buckley U, Waterhouse DF, Crotty T, Keane D
St. Vincent’s University Hospital, Dublin, Ireland
14. Vendor Independent Software for Rapid Comprehensive Assessment of Changes in Left Ventricular Function During
Serial Echocardiographic Studies
Murtagh G, Mor-Avi V, Tsang W, Bhave NM., DeManby B, Kruse E, Yamat M, Lang RM, DeCara JM
University of Chicago, Chicago, Illinois, USA
15. The Association Between Timeliness of Reperfusion Therapy, Left Ventricular Function and In-Patient Mortality of Stemi
Patients Presenting Out of Hours vs Working Hours
Barry T, Lim RY, Fitzpatrick N, Kiernan TJ
University Hospital Limerick, University of Limerick, Graduate Entry Medical School, Ireland
Session 4 Electrophysiology
Chair: Dr Carol Wilson
11.00–11.30 Broad Complex Tachycardia: What is the Mechanism?
Dr Peter O’Callaghan
Cardiff & Vale NHS Trust, Cardiff, UK
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11.30–12.30 Oral Presentations
16. Does the In-Patient Management of Atrial Fibrillation Differ Significantly Depending on Team of Care?
Morgan RB, Faller E, Fenelon A, Mahon C, Blennerhassett L, Curtin L, McMahon G, Murphy RT, Daly CA
St James’s Hospital, Dublin, Ireland
17. Comparison of a Novel 14-day Adhesive Continuous ECG Monitoring Patch to Traditional 24-hour Holter Monitoring in
Symptomatic Arrhythmia Patients
Barrett P, Komatireddy R, Topol EJ
Scripps Translational Science Institute, 3344 N. Torrey Pines Court, Suite 300 La Jolla, CA 92037, USA
18. Prevalence of Atrial Fibrillation and Impact on Clinical and Imaging Characteristics in an Irish Registry of Patients with
HCM
McClelland S, O’Connor S, Keane D
St. Vincent’s University Hospital and Blackrock Clinic, Co Dublin, Ireland
19. Treadmill Exercise Test Measurements as a Diagnostic Tool in Relatives of Long QT Syndrome Patients
1Noonan B, 2Moran D, 2Gallagher M, 2Mahon N, 2Galvin J, 3Watson W, 2McGorrian C
1School of Medicine and Medical Science, UCD, Dublin, Ireland
2Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland
3Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
20. Frequent Premature Atrial Contractions are Associated with Increased Mortality and Recurrent Stroke Following
Ischaemic Stroke/TIA
1Keaney JJ, 2Akijian L, 1Mulholland D, 2Nı´ Chro´inı´n D, 2Hannon N, 2Sheehan O, 1McGorrian C, 1Blake G, 1Mahon N,
3Kyne L, 3Duggan J, 2,3,4,Murphy S, 2Kelly PJ
1Cardiology Department, Mater Misericordiae Hospital, Dublin, Ireland
2Department of Stroke, Mater Misericordiae University Hospital, Dublin, Ireland
3Medicine for the Elderly, Mater Misericordiae University Hospital, Dublin, Ireland
4Royal College of Surgeons in Ireland, Dublin, Ireland
21. Pulse Width Optimisation of ICD Defibrillation Waveform is both a Safe and Effective Programming Strategy at Time of
Implant
Nolan PG, McFadden C, MacNeill BD, Crowley J, Nash PJ, Daly K
University College Hospital, Galway, Ireland
12.30–14.00 Lunch/Exhibition
Session 5 Structural Heart Disease
Chair: Dr Nicola Johnston




22. Is Valve Choice the Main Determinant of Paravalvular Leak Post Transcatheter Aortic Valve Implantation?
Gough A, O’Sullivan K, Barry M, Hurley J, Sugrue D
Mater Misericordiae University Hospital, Dublin, Ireland
23. Renal Sympathetic Denervation Improves Nocturnal Dipping in Hypertensive Patients
Tuohy S, Ryan L, Gleeson J, MacNeill B, Nash P, Daly K, Crowley J, Sharif F
University College Hospital Galway, Galway, Ireland
24. Sutureless Aortic Valve Replacement: A Rapid Deployment, Minimally Invasive Alternative in Surgical Aortic Valve
Replacement
O’ Sullivan KE, Murphy A, Casserley I, Sugrue D, Hurley J
Mater Misericordiae University Hospital, Dublin, Ireland
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25. Resection of Renal Cell Carcinoma Extending into The Heart: Avoidance of Deep Hypothermic Circulatory Arrest
McBride M
Royal Victoria Hospital, Belfast
26. Can Low Volume Adult Congenital Surgery be Delivered Safely in a High Volume Adult Cardiac Surgery Unit?
Austin CR, Wood AE, Graham ANJ
Royal Victoria Hospital, Belfast, NI
27. The St Jude TrifectaTM Aortic Valve: Early Clinical Experience from a Single Centre in the West of Ireland
McVeigh TP, Keita L, Steter D, O’Connor M, Blach A, Kolcow W, Veerasingam D
West of Ireland Cardiothoracic Unit, University College Hospital, Galway, Ireland
15.30–16.00 Poster Presentation
Exhibition/Coffee
28. Clinical Outcomes of Trans-Catheter Aortic Valve Replacement at a Tertiary Cardiac Centre in Ireland
Neylon A, Casserly I, Sugrue D, Hurley J, Blake G, McGorrian C, Moran B, McAdam B, Foley D, Diamond P
Mater Misericordiae University Hospital, Dublin, Ireland
29. Atrial Septal Defect And Left Atrial Appendage Closure: A Single Centre Experience
Ryan N, Mc Adam BF, Foley DP
Beaumont Hospital, Dublin, Ireland
30. Second Generation Left Atrial Occlusion Devices: A Single Centre Experience
Canniffe C, Neylon A, McCann C, Casserly I, Walsh K
Mater Misericordiae University Hospital, Dublin, Ireland
31. Prevalence of Pacemaker Requirement Post Medtronic Corevalve Implantation
Noad RL, Manoharan G, Spence MS
Belfast Health and Social Care Trust, Belfast, NI
32. Audit of Safety and Efficacy Outcomes of Patients Undergoing Left Atrial Box Isolation for Atrial Fibrillation
O’Neill L, Hensey M, Keane D
St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
33. Why Do Patients With Bicuspid Aortic Valve Undergo Surgery?
Canniffe C, Neylon A, O’Neill JO, Nolke L, Redmond M, McCarthy J, Walsh K
Mater Misericordiae University Hospital, Dublin, Ireland
34. Is Post-Mortem Evaluation of Cardiac Rhythm Management Devices Useful?
Nolan PG, Hynes S, Tuohy S, Macneill BD, Nash PJ, Crowley J, Daly K
Galway University College Hospital, Galway, Ireland
35. Implantable Cardioverter-Defibrillators in Heart Transplant Recipients: A Single Centre Experience
Neylon A, Canniffe C, Parlon B, Egan J, McCarthy J, Mahon N, O’Neill JO
Mater Misericordiae University Hospital, Dublin, Ireland
36. Cost-Effective Bridging to Cardiac Transplantation: A Future For Ventricular Assist Devices?
Tracey C, Lawler Z, O’Neill JO, McCarthy J, Egan J, Mahon NG
Mater Misericordiae University Hospital, Dublin, Ireland
37. An Audit of the Prescription of Clopidogrel with Reference to Duration of Therapy and Instructions for Use
1Sutton-Fitzpatrick U, 2Natin S. 2Reilly D
1University of Limerick, Limerick, Ireland, 2General Practice, Limerick, Ireland
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Session 6 Young Investigator Award
Chair: Dr Donal Murray
Judges: Dr John Harold, Dr Patrick O’Gara, Dr. Nick Boon
16.00–17.00 Oral presentations
38. Restoration of Platelet Function with Platelet Transfusion in Acute Coronary Syndrome and Cardiac Surgery Patients on
Dual Antiplatelet Therapy: The APTITUDE Study
O’Connor SA, Martin R, Amour J, Abtan J, Kerneis M, Silvain J, Brugier D, Leprince Pascal, Montalescot G, Collet JP
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re Hospital (AP-HP), Universite´ Paris 6, France
39. Dynamic Surface ECG Markers of Arrhythmogenic Right Ventricular Cardiomyopathy Patients Undergoing Electrophys-
iology Studies
Sugrue A, Finlay MC, Lambiase PD
Institute of Cardiovascular Science, The Heart Hospital, University College Hospital, University of London
40. The Effect of Multiple Micronutrient Supplementation in Patients with Chronic Stable Heart Failure: A Randomized,
Placebo-Controlled Trial
1,3McKeag NA, 1McKinley MC, 1Woodside JV, 2,3Harbinson MT, 1,3McKeown PP
1Queen’s University, Centre for Public Health, Belfast, NI
2Queen’s University, Centre for Vision and Vascular Science, Belfast, NI
3The Heart Centre, Belfast Health &Social Care Trust, Belfast, NI
41. Circulating Endothelial Cell Enriched Gene Expression Analysis in Acute Myocardial Infarction
Barrett PM, Topol EJ
Scripps Translational Science Institute, 3344 N. Torrey Pines Court, Suite 300 La Jolla, CA 92037, USA
17.00–17.30 ICS AGM
17.45–18.45 Stoke Lecture
Atherosclerosis Across 4,000 years of Human History: The HORUS Study of 4 Ancient Populations
Dr. John G Harold




08.00–09.00 Cardiology Education and Training Update
09.00–09.15 Monitoring high radiation dose effects in patients and staff: The new reality for interventional cardiology practice
Dr Paddy Gilligan
Mater Hospital, Dublin, Ireland




09.30–10.00 Stent failure and neoatherosclerosis: Insights from optical coherence tomography and role of novel catheter
therapies
Dr. Robert Byrne
Munich Heart Centre, Germany
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10.00–11.00 Oral presentations
42. Association of Non-Infarct Related Coronary Artery Chronic Total Occlusion with Mortality in Patients Presenting with ST-
Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis
O’Connor SA, Sanguineti F, Garcia AC, Hovasse T, Unterseeh T, Morice MC, Benamer H, Lefe`vre T, Garot P, Louvard Y
Institut Cardiovasculaire Paris Sud: Institut Hospitalier Jacques Cartier, Massy, France
43. Appropriateness of Helicopter Transfer for Primary Percutaneous Intervention
Colleran R, McInerney A, Mulveen V, Daly K
Galway University Hospital, Galway, Ireland
44. Continuous Quality Improvement in the National ACS Programme, The West of Ireland Experience to Date
Colleran R, McInerney A, Mulveen V, Walsh R, Sharif F, Nash P, MacNeill B, Crowley J, Daly K
University College Hospital, Galway, Ireland
45. Retrograde Autologous Prime: Is There an Association Between Improved Haemoglobin Content During Adult Cardiac
Surgery?
Haughey N, Booth K, Jeganathan R
Dept of Cardiac Surgery, Royal Victoria Hospital, Belfast, NI
46. Optical Coherence Tomography in the Days Following Primary PCI; Sobering Findings
Ryan N, Foley DP
Beaumont Hospital, Dublin, Ireland
47. Pre-Hospital Diagnosis of STEMI: Is Electronic Electrocardiogram Transmission Superior to Paramedic Catheterisation
Lab Activation
Colleran R, McInerney A, Daly K
University College Hospital, Galway, Ireland
11.00–11.30 Poster Presentation
Exhibition/Coffee
48. ATOLL Bio-Thrombotic Markers 1
O’Connor SA, Ankri A, Kerneis M, Abtan J, Brugier D, Galier S, Silvain J, Vicaut E, Collet JP, Montalescot G
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re Hospital (AP-HP), Universite´ Paris, France
49. ATOLL Thrombotic Markers 2.
O’Connor SA, Kerneis M, Ankri A, Abtan J, Brugier D, Silvain J, Ecollan P, Vicaut E, Collet JP, Montalescot G
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re Hospital (AP-HP), Universite´ Paris, France
50. Management of Allograft Vasculopathy Post Cardiac Transplant in the Era of Drug Eluting Stents
Canniffe C, Neylon A, Parlon B, Egan J, McCarthy J, Mahon NG, O’Neill JO
Mater Misericordiae Hospital, Dublin, Ireland
51. Application of ESC Guidelines to Rationalise Acceptance Criteria and Streamline Inpatient Cardiac Catheterisation
Tweedie J, Niall Herity N
Belfast City Hospital, Belfast, NI
52. In the Current Era of St Elevation Myocardial Infarction Treatment, What Patients are Not Reperfused? An Observational
Analysis
1McGovern L, 2Kiernan T
1University College Cork, Cork, Ireland, 2University Hospital Limerick, Limerick, Ireland
53. Audit of Rates And Timeframe Of Radial Artery Occlusion Post Radial Angiography
O’Neill L, Chandra R, Fahy C, Mc Carthy-Deering E, Cronin E, Owens P
Waterford Regional Hospital, Waterford, Ireland
54. A Real World Comparison of Outcomes in Transradial Versus Transfemoral Access for Primary PCI: Single Centre
Experience
Colleran R, Durcan R, Judge C, Nolan P, Sharif F
University College Hospital, Galway, Ireland
S366 Ir J Med Sci (2013) 182 (Suppl 8):S359–S392
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55. A Study in Syncope: A Review of 94 Tilt Table Tests
Monaghan M, McCarron M, Purvis J
Departments of Cardiology and Neurology, Altnagelvin Hospital, Western HSC Trust, Londonderry, NI
56. Electrocardiographic Criteria for Predicting Infarct Related Artery Occlusion in Inferior Wall Acute Myocardial Infarction
Elhanan M, Hamra M, Ali M, Murray D
Sligo Regional Hospital, Sligo, Ireland
57. Early Experience of Cardiac Exercise Testing in A Primary Health Care Facility
1O Casaide S, 1Cuddihy B, 2King G, 2Kindler H, 2Clarke J
1Ayrfield Medical Centre Kilkenny, Ireland, 2Eagle Lodge (Aut Even Hospital Kilkenny), Ireland
58. Night Time Blood Pressure And Sub-Clinical Target Organ Damage: Findings from an Irish Primary Care Based Population
Sample
O’Flynn AM, Kearney P, Curtin R, Perry I
University College Cork/Cork University Hospital, Cork, Ireland
59. Retrospective Analysis of Lipid Profiles in Very High Risk Patients Requiring PCI. Are We Adhering to the Guidelines?
Lim RY, Fitzpatrick N, Barry T, Ahern C, Abdalla A, Hussainni A, Lobo R, Stack A, Kiernan TJ, Hennessy T, Meany B,
Abbass S, Hynes B
University Hospital Limerick, Limerick, Ireland
Session 8 Heart Failure/General Cardiology
Chair: Dr Angie Brown




60. STEMI Care in Ireland: Initial Experience of a New National Protocol and Information System
1Jennings S, 2Cavanagh B, 3 Daly K
1Dept of Public Health, HSE; 2HSE South; 3University College Hospital Galway, Ireland
61. Trends in Hospitalisation for Acute MI in Ireland 1997–2008
1Jennings SM, 2Bennett K, 2Lonergan M, 1Shelley E
1Department of Public Health, HSE, Dublin, Ireland; 2Department of Pharmacology and Therapeutics, Trinity Centre for
Health Sciences, St James’s Hospital, Dublin, Ireland
62. A National Evaluation of the Aspirin Response
Kenny D
The National Cardiovascular and Stroke Research Network, RCSI, Dublin, Ireland
63. Poor Cardiovascular Health of Patients Who Begin Haemodialysis in the Mid West Region of Ireland: A Pilot Initiative for a
National Study
Roche D, Lim RY, Yermak D, Casserly L, Cronin C, Hannigan A, Kiernan T, Stack A
Department of Nephrology, Department of Cardiology, University Hospital Limerick, Limerick, Ireland
64. Vortex Formation Time in the Assessment of Patients with Newly Diagnosed Haemochromatosis
1Byrne D, 1Almuntaser I, 1Walsh J, 2Ellis L, 1King G1, 2Norris S, 1Murphy RT
1St James’s Hospital, Dublin, Ireland; 2Gastroenterology, St James’s Hospital, Dublin, Ireland
65. Hospitalisation for Heart Failure: Are We Getting to the Heart of the Matter?
Sugrue A, Havelin A
University College Hospital, Galway, Ireland
13.00 Close of meeting
Ir J Med Sci (2013) 182 (Suppl 8):S359–S392 S367
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Session: Imaging
1. One Year Follow Up of the CAPP study:
A Randomised Controlled Trial Comparing EST
to Cardiac CT
McKavanagh P, Lusk L, Ball PA, Trinick TR, Duly E, Verghis RM,
Agus AM, Walls GM, McCusker S, Orr C, Hamilton A, Harbinson
MT, Donnelly PM
Ulster Hospital, Dundonald, Belfast, NI
Purpose: This is the 1 year follow-up of The Cardiac Computerised
Tomography (CT) for the Assessment of Pain and Plaque (CAPP)
study. [ISRCTN52480460]. The study compared the economic and
clinical outcomes of using cardiac CT compared to Exercise Stress
Test (EST) in stable troponin negative chest pain.
Method: CAPP is a cost-utilisation analysis randomised controlled
trial. 500 patients without known coronary artery disease received
either EST or cardiac CT. All patients were followed up for re-hos-
pitalisations rates and adverse events and for angina symptoms with
the well established Seattle Angina Questionnaires (SAQ).
Results: Of the 500 patients randomised 12 withdrew over the year,
resulting in 245 in the EST arm and 243 in CT arm receiving follow
up. The mean age was 58.3 years and a mean Diamond Forrester
score of 46.4 %. There were with no significant differences in the pre-
test probabilities, age, sex or risk factors. Over the 1 year follow up
period there were 29 Emergency Department (ED) chest pain atten-
dances in the EST arm, with 13 unplanned admissions, compared to 8
ED attendances with 2 unplanned admissions in the CT arm. There
were also more cardiology outpatient attendances in the EST arm.
In the EST arm there were 7 patients who underwent Coronary Artery
Bypass Grafting (CABG) and 12 who had Percutaneous Coronary
Intervention (PCI), compared to 9 CABG and 29 PCI in the CT arm.
At 1 year 408 (81.6 %) patients had returned the SAQ, 210 in the
CT arm and 198 in the EST. There were significant improvements in
the SAQ angina stability and quality of life scores at 1 year in the CT
arm (p B 0.05).
Conclusions: Cardiac CT as an index investigation for stable chest
pain improved angina stability and quality of life, resulting in fewer
planned and unplanned hospital attendances.
2. Prevalence of Cardiac Abnormalities in the Turner
Syndrome Population in Northern Ireland
Noad RL, McManus J, McKeown PP, Muir AR
Belfast Health and Social Care Trust, Belfast, NI
Objectives: There is an increased frequency of cardiac abnormalities
in patients with Turner syndrome. The exact prevalence and sub-
sequent management of these patients, has not been extensively
studied.
Methods: Patients with Turner Syndrome, who attended cardiology,
gynaecology or genetic clinics in the Belfast Trust, were identified
and demographic and clinical data obtained.
Results: 148 patients were identified and divided into groups by
karyotype; group 0 for karyotype unknown (n = 16), group 1 for
monosomy (n = 63), group 2 for mosaic karyotype (n = 26) and
group 3 for structural X chromosome aberrations (n = 43). The mean
age was 28 years (±15.4). The prevalence of cardiovascular risk
factors were: hypertension 8.1 %, hypercholesterolaemia 10.8 %,
diabetes mellitus 5.4 %, ischaemic heart disease 2 %. Cardiac
abnormalities were present in 33.8 % of patients (see table below),
with bicuspid aortic valve the most common (18.2 %), and inter-
vention was required in 8.1 %. Those in group 1 had the highest
incidence of abnormalities and those in group 3 had the lowest.
Conclusions: The prevalence of cardiac abnormalities in Turner
patients greatly exceeds that of the normal population and may be
dependent on karyotype and therefore cardiac imaging and follow



















27 (18.2) 5 (31.2) 13 (20.6) 5 (19.2) 4 (9.3)
Aortopathy 20 (13.5) 6 (37.5) 11 (17.4) 3 (11.5) 0 (0)
Coarctation 14 (9.5) 0 (0) 11 (17.4) 2 (7.7) 1 (2.3)
Patent Ductus
Arterious





8 (5.4) 0 (0) 4 (6.3) 3 (11.5) 1 (2.3)
Ventricular
Septal Defect









1 (0.7) 0 (0) 0 (0) 1 (3.8) 0 (0)
Dissection 1 (0.7) 0 (0) 1 (1.6) 0 (0) 0 (0)
Valvular
abnormality
18 (12.2) 5 (31.2) 9 (14.3) 2 (7.7) 2 (4.7)
Ventricular
impairment
3 (2.0) 0 (0) 2 (3.2) 1 (3.8) 0 (0)
3. Clinical Application of Perfusion CMR in Assessment
of Suspected Coronary Artery Disease
James S, Waterhouse DF, Barrett M, Murphy TM, McAdam B, Foley
DF, Sheahan RS, O’Hanlon R
Centre of Cardiovascular Magnetic Resonance, Blackrock Clinic,
Dublin, Ireland
Introduction: Invasive coronary angiography is the gold standard in
investigation of suspected coronary artery disease (CAD). However,
newer imaging modalities are becoming of greater interest in evalu-
ation of suspected coronary ischaemia as they provide non-invasive
assessment of coronary circulation. In particular, adenosine perfusion
cardiac magnetic resonance (AP-CMR) imaging has shown promise
in evaluation of low-risk patients in whom CAD is suspected. We
therefore wished to determine the prognostic value of normal AP-
CMR in patients with suspected CAD.
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Methods: CMR imaging was performed using a 1.5T GE Scanner
with adenosine stress. Study endpoints included re-hospitalisation for
chest pain, obstructive coronary artery disease on angiography, non-
fatal myocardial infarction (MI) and cardiac death.
Results: Three hundred and seventeen patients (131 female, mean age
47 ± 6.8 years) were enrolled. All patients had suspected CAD and
were deemed to be low-risk. All enrolled patients had a normal AP-
CMR with no stress hypoperfusion, and no delayed enhancement
demonstrated. Indications for CMR included exertional angina,
equivocal exercise stress tests and syncope. On 12-month follow up,
no patients achieved the measured endpoints. Notably, there was no
MI or cardiac death. Additionally, AP-CMR had an excellent safety
profile, with only three patients developing complications, all of
which were minor and did not require specific treatment.
Conclusion: Our data support the utility of AP-CMR as a non-
invasive tool in the investigation of CAD in low-risk patients. A
normal AP-CMR predicts a very low adverse event rate and an
excellent 12-month prognosis in patients with suspected CAD. AP-
CMR may have a role in reducing the number of inappropriate cor-
onary angiographies.
4. Hypertrophic Cardiomyopathy: Clinical
and Imaging Characteristics of an Irish HCM Registry
McClelland S, O’Connor SA, Donohue S, Lavelle L, McErlean A,
Dodd J, O’Hanlon R, Meaney J, McCreery CJ, Clarke J, McDonald
K, Quinn M, Erwin JE, Quigley PJ, Maurer BJ,
Keane D
St. Vincent’s University Hospital, Dublin, Ireland
Background: Hypertrophic cardiomyopathy (HCM) is the most
common inherited cardiac disorder and is the leading cause of sudden
cardiac death (SCD) in the young. HCM is associated with significant
heterogeneity in terms of phenotypic expression and clinical course,
and clinical characteristics may differ among HCM populations
internationally. It is important, therefore, to establish a registry to
characterise the HCM population in Ireland.
We have previously presented data from a registry comprising 99
HCM patients (O’Connor, 2011). Here we present a comprehensive
analysis of an expanded registry of 162 patients, describing patient
demographics, risk factors for SCD, ICD discharge events, echocar-
diographic and cardiac MRI (CMR) characteristics.
Methods: Patients with HCM were identified in St Vincent’s University
and Private Hospitals, and Blackrock Clinic by review of patient
records, CMR, echocardiogram, holter and ICD reports. Clinical
details, symptom status, imaging indices and ICD data were recorded.
Results: 162 patients with HCM were identified. The majority
(63.6 %) were male. Median age at registration was 59 years (range
17–90 years). Risk factors for SCD were prevalent: 39 patients
(24.1 %) had documented non-sustained ventricular tachycardia
(NSVT), 15 had history of syncope (9.3 %), 48 had family history of
HCM (29.6 %), 33 had family history of SCD (20.4 %), 1 had an
aborted SCD (0.6 %), 2 patients (1.2 %) had LV wall thickness of
[30 mm, and 4 of 59 patients (6.8 %) who underwent exercise stress
test had a hypotensive response to exercise.
Atrial fibrillation (AF) was documented in 56 patients (34.6 %). The
prevalence of CVA and TIA was 6.8 and 4.9 %, respectively.
Symptom status was known for 126 patients. The majority (75.4 %)
were NYHA Class I, 21.4 % were NYHA Class II and 3.2 % NYHA
Class III. Chest pain, palpitations and pre-syncope were present in
25.4, 14, and 6.2 %, respectively.
47 patients (29 %) had ICDs in situ. Shocks were documented in 13
patients (27.7 %). 11 (84.6 %) had experienced an inappropriate
shock, the main trigger for which was AF (63.6 %).
Echocardiogram reports were available for 127 patients. The average
ejection fraction (EF) was 65.7 ± 0.91 %. Systolic anterior motion
(SAM) of the mitral valve was documented in 28.3 % of cases. 29
patients (17.9 %) had LVOT outflow obstruction[30 mmHg. Average
dimensions were as follows: left atrial diameter 44.1 ± 1.03 mm,
LVEDD 47.34 ± 0.66 mm, LVESD 29.5 ± 0.64 mm, IVSD
18.48 ± 0.55 mm, posterior wall thickness 12.65 ± 0.45 mm.
93 patients underwent CMR. The presence and extent of myocardial
fibrosis, as demonstrated by late gadolinium enhancement (LGE) had
been shown to have prognostic significance in HCM (O’Hanlon et al.).
Fibrosis was demonstrated in 63 patients (67.7 %), SAM in 25 cases
(26.9 %) and right ventricular involvement in 7 cases (7.5 %). Aver-
age EF was 68.73 ± 1.22 %. Cardiac dimensions were as follows:
Maximal wall thickness was 19.56 ± 0.66 mm, Anterior septal wall
thickness 18.39 ± 0.86 mm, Posterior septal wall thickness
9.98 ± 1.06 mm, End diastolic 49.61 ± 1.02 mm, End systolic
dimension 28.86 ± 1.05 mm, Left atrial diameter 38.9 ± 1.2 mm.
Asymmetric septal HCM was the most common morphological var-
iant. Apical-variant HCM was present in 19 patients (20 %), a higher
proportion than reported in other Western cohorts.
Conclusion: These data expand significantly on the initial report from
this registry, providing comprehensive baseline characteristics for the
Irish HCM cohort. Important findings include the high prevalence of AF
and CVA, and the high proportions of patients with myocardial fibrosis,
SAM and apical-variant HCM. To our knowledge this is the largest
cohort of patients with HCM in Ireland, and the continued expansion of
this registry with regular reporting of data will provide a valuable means
by which to document, analyse, and prospectively evaluate the char-
acteristics and outcomes of the HCM population in Ireland.
5. T1 Mapping Detects Myocardial Oedema in a Rat
Model of Myocardial Ischaemia
O h-Ici D, Jeuthe S, Kozerke S, Kuehne T, Berger F,
Messroghli D
German Heart Institute, Berlin; King’s College, London, UK;
University and ETH Zurich, Switzerland
Purpose: Ischemic cell death is characterized by cellular oedema.
Cardiovascular magnetic resonance (CMR) can be used to detect
oedema using T2 weighted imaging, but this technique has a number
of technical limitations. T1 mapping is a quantitative measurement
which car directly reflects the amount water in a tissue. Changes in T1
reflect changes in tissue composition. Our aim was to study the
development of oedema in a small animal model of myocardial
Ischemia.
Methods: Rats (n = 8) underwent coronary occlusion for 30 min
followed by 60 min of reperfusion to delineate the time course of
development of changes in non-contrast T1 abnormalities. T1 was
quantified by 3.0 T CMR (Phillips) using a Small Animal Look-
Locker Inversion Recovery (SALLI) sequence. T1 was quantified
over time starting from baseline prior to occlusion in the remote zone
and in the area at risk.
Following the experiment the hearts were removed. The coronary
artery was reoccluded to allow delineation of the area at risk with
evans blue, then stained using triphenyltetrazolium chloride (TTC).
This defined 1-Area at Risk, 2-Infarction [white], 3-Salvaged myo-
cardium [stained red from TTC], and 4-Remote [Stained blue].
Results: On coronary occlusion all rats developed myocardial
ischemia initially confirmed by ECG changes and ventricular
arrhythmia. Fatal arrhythmia occurred in 2 Rats.
During occlusion T1 increased in the area at risk (p \ 0.001). This
increase was noted within the first 10 min of coronary occlusion and
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remained unchanged during the 30 min period of ischemia (p = 0.74)
and following reperfusion at 30 (p = 0.83) and 60 min (p = 0.81).
Conclusions: During coronary occlusion, T1 increases in the area at
risk consistent with the formation of ischemia. This change is
noticeable with 10 min of coronary occlusion. T1 mapping is a robust
quantitative method to detect the effects of myocardial ischemia.
6. Clinical Outcomes of Patients with Low-Flow, Low
Gradient Severe Aortic Stenosis and Either Preserved
or Reduced Ejection Fraction Undergoing TAVR
*O’Sullivan CJ, *Stortecky S, Heg D, *Pilgrim T, *Hosek N,
*Zanchin T, *Meier B, *Windecker S, *Wenaweser P
*Swiss Cardiovascular Centre, Bern University Hospital,
Clinical Trials Unit, Bern University Hospital, Switzerland
Objectives: We aimed to assess the safety and efficacy of trans-
catheter aortic valve implantation (TAVI) among patients presenting
with paradoxical low-flow, low-gradient, severe aortic stenosis (AS)
(PLFAS) and classical low-flow, low-gradient severe AS (LFLG).
Background: The clinical outcomes of patients presenting with low-
gradient severe AS undergoing TAVI are unclear.
Methods: Of 533 symptomatic patients undergoing TAVI, 385 had a full
pre-procedural right and left heart catheterization. 208 patients had high-
gradient AS (HGAS; mean gradient [MG] ‡40 mmHg), 85 had PLFAS
(MG £40 mmHg, indexed aortic valve area [iAVA] £0.6 cm2 m-2,
stroke volume index £35 ml/m2, ejection fraction (EF) ‡50 %) and 61
had LFLG (MG £40 mmHg, iAVA £0.6 cm2 m-2, EF £40 %).
Results: Compared with HGAS, PLFAS and LFLG had higher sys-
temic vascular resistances (HGAS: 1912 – 654 vs PLFAS:
2006 – 586 vs LFLG: 2216 – 765 dyne s cm-5, p = 0.007) but
lower valvulo-arterial impedances (HGAS: 7.8 – 2.7 vs PLFAS:
6.9 – 1.9 vs LFLG: 7.7 – 2.5 mmHg mL-1 m-2, p = 0.027). At
30-days, no differences in cardiac death (6.5 vs 4.9 vs 6.6 %,
p = 0.90) or death (8.4 vs 6.1 vs 6.6 %, p = 0.88) were observed
among HGAS, PLFAS and LFLG groups, respectively. At 1-year,
New York Heart Association functional improvement occurred in
most surviving patients (HGAS: 69.2 % vs PLFAS: 71.7 % vs LFLG:
89.3 %, p = 0.09) and no significant differences in overall mortality
were observed (17.6 %, vs 20.5 %, vs 24.5 %, p = 0.67). Compared
with HGAS, LFLG had a higher 1-year cardiac mortality (adj hazard
ratio 2.45, 95 % confidence interval 1.04–5.75, p = 0.04).
Conclusions: TAVI in PLFAS or LFLG patients is associated with
clinical outcomes comparable with HGAS patients and all groups
profit symptomatically to a similar extent.
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7. In-Vivo Study of Myocardial Metabolic Changes
in a Rat Model
O h-Ici D, Weiss K, Sigfridsson A, Wissman L, Busch J, Messroghli D,
Kozerke S
German Heart Institute, Berlin; King’s College, London, UK;
University and ETH Zurich, Switzerland
Background: Hyperpolarized 13C-labeled tracers offer the first
method to measure cardiac substrate metabolism in real time and
in vivo (1). Understanding the metabolic changes that occur in
myocardial ischemia could help in diagnosis and treatment. Our aim
was to study if the regional metabolic changes that occur following
coronary occlusion were detectable in a small-animal model.
Methods: Myocardial metabolism was studied with MRS using Rats
(n = 6) who were injected with 2 ml of 90 mM hyperpolarized [1-
13C] pyruvate over 7 s via a tail vein before and after coronary
occlusion. The left coronary artery was occluded for 30 min for create
myocardial ischemia followed by reperfusion using a closed chest
method (2). Scanning was performed using a horizontal bore 9.4T
Bruker Biospec system with a 13C/1H radiofrequency (RF) volume
coil and a 13C receive surface coil placed over the heart. ECG, res-
piration rate, and body temperature were monitored throughout the
experiment. Anatomical images were acquired prior to 13C-imaging
for spatial localization of the heart and correct coil positioning. To
investigate the metabolic changes in ischemia, hyperpolarized (13)
C-labelled pyruvate was injected prior to coronary occlusion, fol-
lowing reopening of the coronary artery. The dynamic time series
were acquired by collecting 13C spectra prior to each injection of
hyperpolarized [1-13C] pyruvate. The MRS-images with hyperpo-
larised [1-13C] pyruvate were acquired in a short-axis view of the
heart using a cardiac- and respiratory-gated CSI pulse sequence. [1-
13C] pyruvate was hyperpolarized using a custom built DNP system.
Following the experiment the hearts were removed. The coronary
artery was re-occluded to allow delineation of the area at risk and
staining for myocardial infarction. This was then correlated with the
metabolic maps.
Results: Before infarction, a uniform and myocardium specific distri-
bution of the lactate and alanine signal was detected in the metabolite
maps over the anterior wall of the left ventricle. After ischemia the
signal from alanine, and bicarbonate was reduced, with an increase in
lactate, whereas, in the region not affected by infarction, the signal
levels were comparable to the levels before coronary occlusion.
Conclusion: This study demonstrates that hyperpolarized 13C MRS
can be used to visualize regional changes in cardiac metabolism in
rats after myocardial infarction. This method holds promise for the
investigation of ischemic heart disease, and may provide a role in
guiding future therapies.
8. Significant Radiation Dose Reductions in Advanced
Cardiac CT Imaging—Are We Keeping Up
with the Guidelines. Our Experience with Ireland’s
Only 320 Slice
Kindler H, King G, Clarke J
Eagle Lodge Cardiac Centre, Limerick, Ireland
Introduction: We report our experience with Irelands first and only
320 Slice Multi Detector Row scanner in Advanced CT Coronary
Angiography (CTCA).
CTCA is increasingly used in the non-invasive assessment of patients
with suspected coronary artery disease and low to intermediate Fra-
mingham risk of CAD. It is possible to achieve significant dose
reductions with careful adjustment of several scanning parameters.
We report our experience of significant dose reductions with currently
available CT technology and discuss possible future areas of study
and quality improvement in Cardiac CT Angiography.
Methods: Prospective unselected enrolment of 100 patients attending
for routine scanning for first assessment of significant coronary ste-
nosis for Calcium scoring & CTCA. Small FOV, 85 kV, Dynamically
triggered volume acquisition, prospectively gated CT data acquisition
protocol in one single heart beat.
Results: (N = 100) Average(±)SD:
Age 56 yr(±)9, HR 56 bpm, KV:85(±)9 Average total body dose
(1.71 mSv(±) 0.26, min 0.7, max 2.7. (mA)69(±)30.
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Conclusion: It is possible to significantly reduce radiation dose for a
comprehensive cardiac CT study compared with current practice yet benefit
from an increase in detector density and higher resolution (0.5 9 0.5 mm).
The total dose of CT angiography with our method is 23 % lower than the
Calcium score alone. We propose that further dose reductions are possible
by reducing the tube voltage of the calcium scan from the standard 120
described initially by Agatston in 1990 to 80 kV without significantly
compromising signal to noise (SNR) or contrast to noise (CNR) ratio.
9. Exposure to Ionizing Radiation when Monitoring
for Chemotherapy-Related Cardiotoxicity Using
Multigated Acquisition Scanning: Does It All Add Up?
Murtagh G, Addetia K, Yu Z, DeCara J
University of Chicago, Chicago, Illinois, USA
Background: Anthracyclines and trastuzumab are central to breast
cancer treatment but can be cardiotoxic. Sequential measurements of
Left Ventricular Ejection Fraction (EF) using either Transthoracic
Echocardiography (TTE) or Multigated Acquisition (MUGA) scans are
advised while on trastuzumab. No international guidelines exist to aid in
deciding which modality to use, but clinical trial protocols indicate that
the same modality should be employed throughout treatment. MUGA is
associated with lower inter- and intra- observer variability, but each
scan results in exposure to approximately 8 mSv ionizing radiation. The
maximum recommended dose per year for those working with radio-
active materials is 50 mSv; however cancer patients may also undergo
Computed Tomography (body-approximately 10 mSv). Few Irish
hospitals currently employ MUGA, but TTE services are stretched and
questions are being raised as to whether MUGA would be preferable.
The aim of this study was to review the use of TTE and MUGA at a
centre where both are employed, and evaluate radiation exposure.
Methods and Results: Electronic records from breast cancer patients
treated with anthracyclines and/or trastuzumab from January
2010-January 2012 at a tertiary hospital in the US were reviewed. Those
whose cardiac imaging was performed elsewhere were excluded.
Of 80 patients, 38 (48 %) had sequential TTEs performed, 31 (39 %)
MUGA and the remaining 11 (13 %) both TTE and MUGA per-
formed while on treatment. The mean number of MUGA scans per
patient was 1.8 ± 1.2 and TTEs 2.3 ± 1.4. Among those in whom
Cone MUGA was performed, the mean radiation dose was
41 ± 19 mSv and 7(9 %) were exposed to over 50 mSv radiation in
1 year. The contribution made by MUGA was not insignificant in
these 7 (average 3 scans = 24 mSv).
Conclusions: The contribution made by MUGA scans to total radi-
ation exposure should be considered in cancer patients. TTE is likely
preferable for patients in whom extracardiac imaging incorporating
radiation exposure is being planned.
10. Increased Anteroseptal Wall Thickness in HIV
Positive Males Compared to Healthy Male Controls
Morgan RB, Loy A, O’Dea S, Mulcahy F, Meaney J, Daly CA
St James’s Hospital Dublin, CAMI St James’s Hospital, Dublin,
Ireland
Introduction: In the HIV positive patient cardiovascular disease is a
complex multifactorial process with many possible contributors.
Aim: To study an asymptomatic group of HIV positive men on anti-
retroviral therapy (ART) and compare them to age and sex matched
controls in order to detect underlying cardiovascular (CV) disease.
Methods: Prospective cohort study of asymptomatic HIV positive
men on ART compared to male controls. Baseline demographics, 12
lead ECG, routine biochemistry, NT-proBNP, fasting lipids and
glucose were recorded. Images were acquired on a 3T Achieva Philips
scanner with 5 channel phase array cardiac coil and weight based IV
gadolinium was given at 0.15 mmol/kg dose with post contrast
inversion recovery imaging after 10 min. Philips Viewforum software
was used for post processing. Diastolic function was assessed using
phase contrast analysis of mitral inflow to calculate E:A ratio.
Results: HIV patients (n = 168) were matched for age, sex and
traditional CV risk factors (table 1). There was no significant differ-
ence in left ventricular volumes or late gadolinium enhancement
(LGE) of the myocardium, although a number of clinically significant
cases (n = 7) were detected. Increased anteroseptal (AS) wall
thickness (table 1) in cases compared to controls may indicate early
myocardial fibrosis or triglyceride deposition which warrants further
investigation using MR spectroscopy in these patients. Factors which
predicted increased AS on multiple linear regression included positive
family history (p = 0.046), increased BMI (p = 0.001) and increased
Framingham risk score (p = 0.035).
Conclusion: Increased AS wall thickness in HIV positive patients
may be an early marker for myocardial fibrosis or triglyceride
deposition. Further investigation with MR spectroscopy is warranted
in these cases.
Cases (168) Controls (34) P value
Age (mean, years ± SD) 46.49
(±8.68)
43 (±8.5) *0.03
Smoking (pack years) 13.7 (±17.7) 5.58 (±9.41) *\0.001
Hypertension (%) 16.7 11.8 0.648
T2DM (%) 6 5.9 1.0
BMI (mean ± SD) 25.65 (±3.5) 27.25 (±3) *0.016




FamHx (%) 38 26.2 0.225
TRIG (mmol/l) 1.82 (±1.2) 1.48 (±0.97) 0.218
LVEF (mean, %) 65.7 (±5.64) 66 (±6.46) 0.8
E/A ratio (mean) 1.33 (±0.46) 1.44 (±0.4) 0.144
Mean AS (mm) 10.7 (±2) 9.8 (±1.93) *0.021
LGE (%) 4.16 0 0.605
Table 1 Results. T2DM = type 2 diabetes, FamHx = family his-
tory of premature CAD, TRIG = hypertriglyceridaemia. LVEF = left
ventricular ejection fraction. AS = anteroseptal wall thickness.
11. Serum Amyloid P-Component Update: Potential
Mechanism by Which SAP Attenuates LV Remodelling
in Hypertensive Heart Disease
Horgan S, Watson C, Glezeva N, Neary R, Ledwidge M,
McDonald K, Baugh J
Conway Institute, University College Dublin, Dublin, Ireland
Purpose: Last year, we showed that treatment with serum amyloid
P-component (SAP) inhibits deposition of perivascular collagen and
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reduces cardiomyocyte hypertrophy in spontaneously hypertensive
rats. We hypothesised that these beneficial effects related to a
reduction in pro-fibrotic macrophages evidenced by lower serum
levels of chemotactic proteins and a reduction in macrophage staining
in the myocardium. We are currently investigating a mechanism
in vitro and present our findings to date.
Methods: Rat alveolar macrophages (NR8383) are treated with var-
ious cytokines to induce polarisation to a specific functional
phenotype. Rat neonatal cardiomyoblasts (H9c2) are incubated with
various phenylephrine and conditioned macrophage media combina-
tions. SAP is introduced at different stages of the experiment.
Cardiomyoblasts are stained by immunofluorescence and mean cell
area estimated with ImageJ software. Quantitative real time poly-
merase chain reaction is used to determine genetic expression of
macrophage phenotypic markers and hypertrophic genes.
Results: A 50 % increase in cell area is found in cardiomyoblasts
treated with phenylephrine (p \ 0.001). Nuclear area is also
increased (p \ 0.01). SAP does not affect cellular area in cardio-
myoblasts treated with or without phenylephrine. Macrophages
incubated in medium with interferon-c and lipopolysaccharide have a
marked increase in iNOS and IL1b expression compared to controls.
Cardiomyoblasts incubated in this M1 macrophage conditioned
media have increased cellular area (p \ 0.001). Macrophages incu-
bated in medium containing IL4, IL10, IL13 and dexamethasone
assume an alternative/M2 macrophage phenotype. Expression of the
cell surface receptor CD206 is found to be increased in these sub-
types and how they influence cardiomyoblast morphology is under
investigation.
Conclusions: While SAP does not exert any direct effect on cell size,
factors secreted by the pro-inflammatory M1 macrophage phenotype
appear to promote cardiomyoblast hypertrophy. It is likely that SAP
indirectly attenuates cellular hypertrophy via its effect on macro-
phages. The impact of SAP on LV remodelling by influencing
macrophage behaviour continues to be examined.
12. Adverse Impact of Smoking on Mortality
and Kidney Transplantation Among Patients with and
without Cardiovascular Disease in End Stage Kidney
Disease
Roche D, Lim RY, Yermak D, Casserly L, Cronin C, Hannigan A,
Kiernan T, Stack A
University Hospital Limerick, Limerick, Ireland
Background: Smokers experience higher rates of adverse outcomes
than non-smokers in the general population. The extent to which
smoking contributes to adverse outcomes among new patients with
pre-existing cardiovascular disease approaching ESKD has not been
fully explored. The aim of this study was to investigate the clinical
impact of smoking on the risks of mortality and kidney transplanta-
tion among US patients with and without clinical cardiovascular
disease at dialysis initiation.
Methods: National data on 823, 753 incident dialysis patients
between May 1995 and December 2004 and followed until October
31, 2006, were analyzed from the United States Renal Data System.
Patients with the following clinical cardiovascular conditions were
identified at dialysis initiation: coronary artery disease, peripheral
vascular disease and stroke. Multivariable Cox regression evaluated
the relative hazard ratios (HR) for death and kidney transplantation at
2 years follow-up stratified by cardiovascular condition and by
smoking status.
Results: The mean age was 62.8 years old, 54 % were male, and the
majority were white. Adjusted mortality risks were significantly
higher for patients with cardiovascular conditions who continued to
smoke compared with those who did not and remained significant
following multivariable adjustment. Conversely, the risks of kidney
transplantation were significantly lower for all patients with known
cardiovascular disease and in particular those who continued to
smoke as described below:
Smoker Non Smoker Smoker Non Smoker
Hazard Ratio for Death
CAD 1.5 1.26 1.25 1
PVD 1.55 1.34 1.22 1
Stroke 1.25 1.53 1.33 1
Hazard Ratio for Kidney Transplantation
CAD 0.66 0.55 0.32 1
PVD 0.33 0.44 0.32 1
Stroke 0.35 0.48 0.61 1
Conclusions: Continued smoking among new dialysis patients with
cardiovascular conditions is associated with adverse clinical outcomes
and reduced lifespan. Preventative strategies directed at smoking
cessation should be aggressively pursued at all stages of CKD to
improve patient survival.
13. Renal Artery Sympathetic Nerve Anatomy in The
Human: A Histologic Post-Mortem Study to Guide
Future Catheter Denervation Strategies
Roy AK, Cunningham M, Buckley U, Waterhouse DF, Crotty T,
Keane D
St. Vincent’s University Hospital, Dublin, Ireland
Background: Although catheter-based renal artery denervation is an
effective therapy for drug-resistant hypertension, gaps still exist in our
understanding of the pathophysiology of renal nerve injury, as well as
ideal methods and locations to deliver optimal thermal tissue modu-
lation. In this novel study we describe in detail the anatomy of the
human renal artery sympathetic plexus, under physiologic perfusion
conditions.
Methods: Post-mortem renal arteries (N = 9) were harvested en bloc,
and formalin fixed using a perfusion fixation system. Three anatom-
ical blocks were made through the arteries- distal, mid, and proximal,
with gross anatomy analyzed using Haematoxylin and Eosin stains,
followed by specific immunohistochemistry staining for identification
of afferent/efferent nerve plexuses (tyrosine hydroxylase, CGRP,
Substance P). Nerve distance from the lumen was measured, as well
as segmental nerve densities along the length of the renal artery. We
then compared the differences in plexus location between perfusion
fixed and the non-fixed samples, and examined potential variations
between our human samples and reported porcine renal artery nerve
anatomy.
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Results: The luminal to nerve diameters, segmental nerve densities,
as well as patient characteristics are presented in Table 1. The renal
artery blocs were carefully debulked (Figure 1), and Figure 2 dem-
onstrates the standard measurements as described (with basic H and E
stains).
Conclusion: This novel human post-mortem study describing histo-
logic and spatial locations of renal artery sympathetic nerve plexuses
under physiological conditions may help to guide future catheter
denervation strategies.
14. Vendor Independent Software for Rapid
Comprehensive Assessment of Changes in Left
Ventricular Function During Serial Echocardiographic
Studies
Murtagh G, Mor-Avi V, Tsang W, Bhave NM, DeManby B,
Kruse E, Yamat M, Lang RM, DeCara JM
University of Chicago, Chicago, Illinois, USA
Background: Sequential evaluation of left ventricular (LV) function
is critical in patients receiving potentially cardiotoxic treatments.
However, identification and interpretation of the clinical significance
of subtle changes in LV function from echocardiographic images is
time-consuming and requires training. The aim of this study was to
develop and test a new approach aimed at addressing this issue.
Methods and Results: Dedicated semi-automated software was
developed (Epsilon Imaging), which analyzes images obtained during
serial examinations and provides a visual, easy-to-understand display
of changes in LV ejection fraction (EF), peak systolic global longi-
tudinal strain (GLS) or both. To test this software, 30 subjects who
had 2 echocardiographic studies separated by C4 weeks were iden-
tified and their images analyzed. An expert echocardiographer
reviewed EF and GLS data separately using commercial software
(Philips QLab), and classified EF and/or GLS in each patient as
unchanged, improved or worsened. This classification was used as a
reference to test the accuracy of using a combined display of changes
in EF and GLS (see image). This was performed by an inexperienced
observer with and then without the dedicated software.
Image analysis and interpretation were faster using the dedicated
software (27 ± 5 vs 15 ± 5 min). The agreement with the reference
was slightly better with the dedicated software (93 %; kappa = 0.90)
than without it (90 %; kappa = 0.87).
Conclusions: Combined displays of changes in EF and GLS data
from serial studies allows quick, easy and accurate interpretation of
changes in LV function, promising to improve follow-up of
patients undergoing potentially cardiotoxic treatments such as
chemotherapy.
15. The Association Between Timeliness of Reperfusion
Therapy, Left Ventricular Function and In-Patient
Mortality of Stemi Patients Presenting Out of Hours vs
Working Hours
Barry T, Lim RY, Fitzpatrick N, Kiernan TJ
University Hospital Limerick, University of Limerick, Graduate Entry
Medical School, Ireland
Aim: The aim of our study was to compare the outcomes in STEMI
patients presenting to the ED during working hours versus those
presenting out of hours.
Method: We retrospectively analysed data relating to 184 patients
presenting to UHL with STEMI between January 2011 and October
2012. The mean age was 62 years (±11.6) with a male preponderance
of 73 %. 90 (49 %) patients presented outside of working hours
(OWH) and 94 patients (51 %) presented inside working hours
(IWH).
Results: The overall in-hospital mortality rate was 4.9 % (9/184).
There was no significant difference with respect to in-hospital mor-
tality (4.3 % IWH Vs 5.56 % OWH, p = 0.683). The IWH group
were more likely to receive PPCI (55.4 % Vs 8.9 %). Thrombolysis
was utilized more commonly in the OWH group (64 % Vs 25 %). Of
those that were thrombolysed during working hours 66.7 %
(16)achieved a door-to-needle time of less than thirty minutes com-
pared with 67 % (39) in the OWH Group. In reference to the patients
receiving PPCI 62.5 % (5) achieved a door-to-balloon time of less
90 min in the OWH group compared with 65.4 % (34) in the IWH
group. We examined each patient’s ejection fraction (E.F.) after
admission and/or during follow-up. We found that 14.9 % (n = 25)
had significant LV Dysfunction (E.F. \35 %). Of this group, 56 %
presented during OWH (44 % IWH).
Conclusion: In conclusion, despite having significant difference in
modality of reperfusion therapy, we found no significant difference in
terms of mortality or E.F. in patients presenting within working hours
vs those presenting outside working hours.
Fig. 2Fig. 1
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16. Does the In-Patient Management of Atrial
Fibrillation Differ Significantly Depending on Team
of Care?
Morgan RB, Faller E, Fenelon A, Mahon C, Blennerhassett L,
Curtin L, McMahon G, Murphy RT, Daly CA
St James’s Hospital, Dublin, Ireland
Background: Atrial fibrillation (AF) is the most common sustained
arrhythmia, with significant impact on morbidity and health costs. Its
management varies widely and becomes ever more important as its
prevalence grows with an increasingly ageing population.
Aim: To assess the outcome of patients with AF and any variation
depending on the medical team managing the condition during an
acute admission.
Methods: Prospective observational study in a Dublin university
teaching hospital. Consecutive patients over 4 time individual
points(Dec, Mar, June, Sept) with AF detected on admission ECG or
on telemetry were included. Patient demographics, clinical details,
treatment and initial outcomes were recorded.
Results: 346 patients with known or new AF were identified. Mean
age 75.5 ± 11.4 years (range 29–103). 53 % male. Mean length of
stay 13 (±26) days. AF was the primary reason for admission/
attendance in 23.4 % of cases. Of these 41 % were managed by the
medical team on call, 40 % by cardiology and 19 % by the emer-
gency department. Patients managed medically were more likely to
have a longer LOS (p \ 0.001), to be on digoxin on discharge
(p \ 0.001) and to be readmitted within 30 days (p = 0.015). Those
managed by cardiology were more likely to have an echo done
during stay (p \ 0.001), left heart cath (p \ 0.001), inpatient car-
dioversion (p = 0.014), PPM insertion (p = 0.005) and flecainide
on discharge (p \ 0.001). They were also more likely to be in sinus
rhythm on discharge (p \ 0.001). There was no significant differ-
ence in incidence of TOE, R heart cath, AF ablation, prescription of
amiodarone, ACE inhibitors, or warfarin on discharge depending on
team of care.
Warfarin prescribing rate at discharge was 50.3 %. Factors predictive
of non prescription of warfarin despite an indication as per ESC
guidelines include older age (p \ 0.001), female gender (p = 0.064),
type of AF (permanent [ acute [ PAF [ persistent) (p \ 0.001) and
absence of concomitant CCF on CXR at presentation (p \ 0.001).
Mean CHADS and CHADSVASC scores were 2.31 ± 1.2 and
3.85 ± 1.7 respectively. Mean HASBLED score was 2.32 ± 1.1.
Conclusion: The management of patients with AF presenting to the
ED varies widely depending on primary team of care. This likely has
a significant impact on cost of inpatient care and warrants further
study.
17. Comparison of a Novel 14-day Adhesive Continuous
ECG Monitoring Patch to Traditional 24-hour Holter
Monitoring in Symptomatic Arrhythmia Patients
Barrett P, Komatireddy R, Topol EJ
Scripps Translational Science Institute, 3344 N. Torrey Pines Court,
Suite 300 La Jolla, CA 92037, USA
Background: The transient, sporadic nature of arrhythmias render
them difficult to detect and characterize using traditional, 24 h holter
monitoring due to limitation that include the need for patients to
wear cumbersome electrodes, a short monitoring window, and lim-
itations placed on patient activity. Clinically significant arrhythmias
are often missed. The Zio Patch is an FDA approved adhesive,
light weight, single-use, one lead ECG monitor that is worn on a
patient’s chest for up to 14 days continuously recording cardiac
rhythm. No additional wires or external electrodes are needed. Use
of this adhesive patch in patients referred for ambulatory cardiac
monitoring should provide a higher diagnostic yield when compared
to holter monitoring.
Methods: 146 patients with suspected arrhythmias wore both a
holter monitor for up to 24 h and an adhesive patch monitor for
14 days. Data from both the holter monitor and the adhesive patch
was analyzed for the detection of six arrhythmias including atrial
fibrillation, supraventricular tachycardia, atrioventricular block,
pauses, ventricular tachycardia and ventricular fibrillation. McNe-
mar’s test was used to determine if differences exist between
detection in the adhesive patch and the holter, with a significance
level of 0.05.
Results: Of the 146 patients 64 % (93) had at least one of the 6 pre
specified arrhythmia detected by the adhesive patch monitor and
44 % (64) by the holter monitor (p \ 0.01). There were 39 (27 %)
clinically relevant arrhythmias (SVT excluded) detected by the
adhesive patch and 28 (19 %) by the holter (p = 0.01).
Conclusion: Use of a 14 day adhesive patch monitor as compared to
conventional holter monitoring identified significantly more of the
two groups of pre specified arrhythmias in patients referred for
ambulatory cardiac monitoring.
18. Prevalence of Atrial Fibrillation and Impact
on Clinical and Imaging Characteristics in an Irish
Registry of Patients with HCM
McClelland S, O’Connor S, Keane D
St. Vincent’s University Hospital and Blackrock Clinic, Dublin,
Ireland
Background: Atrial fibrillation (AF) is the most common sustained
arrhythmia in patients with hypertrophic cardiomyopathy (HCM).
Development of AF is associated with deterioration of clinical status
and outcome. In HCM patients, increased left atrial size, age, and
congestive heart failure symptoms are independent predictors of
occurrence of AF. Here we report the prevalence and impact of AF in
a 162-patient Irish HCM registry.
Methods: A registry of 162 patients with HCM attending St Vin-
cent’s University and Private Hospitals and Blackrock Clinic was
generated and medical notes, echocardiogram, cardiac MRI (CMR)
and implantable cardioverter-defibrillator (ICD) records were
reviewed. Data are mean ± SEM, P \ 0.05 indicated statistical
significance.
Results: The prevalence of AF was 34.6 %. In AF patients, there was
a male preponderance (61 vs 42 %) and trend towards increased age
(59.7 ± 2.0 v 55.6 ± 1.7 years, P = 0.06).
AF patients were more likely to be symptomatic with 32.6 and 6.5 %
in NYHA Class II or III, respectively, compared with 13.3 and 1.3 %
of non-AF patients.
100 % of CVAs occurred in patients with AF, with a prevalence of
19.6 % in AF-patients.
Ejection fraction (EF) was significantly reduced in patients with AF
compared with non-AF patients, measured by echocardiogram
(60 ± 1.7 % vs 67.9 ± 0.9 %, P = 0.0000007) and CMR
(61.2 ± 2.9 % vs 72 ± 1 %, P = 000012).
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Left atrial diameter was significantly increased in AF patients, mea-
sured by echocardiogram (49.5 ± 1.8 mm vs 40.52 ± 1.05 mm,
P = 0.000006) and CMR (46.2 ± 2.4 mm vs 36.4 ± 1.2 mm,
P = 0.00009).
Myocardial fibrosis was detected by late gadolinium enhancement
on CMR in 85.7 % of patients with AF, versus 60 % of non-AF
patients.
Of those AF patients who received inappropriate ICD shocks, 100 %
received shocks triggered by AF.
Conclusion: AF is common in the Irish HCM population, and is
associated with increased risk of stroke, symptom deterioration and
inappropriate ICD discharge. We have confirmed its association with
increased myocardial fibrosis, reduced EF and increased LA diameter
in this cohort.
19. Treadmill Exercise Test Measurements
as a Diagnostic Tool in Relatives of Long QT Syndrome
Patients
1Noonan B, 2Moran D, 2Gallagher M, 2Mahon N, 2Galvin J,
3Watson W, 2McGorrian C
1School of Medicine and Medical Science, UCD, Dublin, Ireland;
2Department of Cardiology, Mater Misericordiae University Hospital,
Dublin, Ireland; 3Department of Cardiology, Connolly Hospital,
Blanchardstown, Dublin, Ireland
Introduction: Long QT Syndrome (LQTS) is an inherited genetic
disorder associated with arrhythmia and sudden cardiac death risk.
Diagnosis is made on clinical evaluation. More recently, new
diagnostic criteria using treadmill exercise test information have
been published. We aimed to examine the predictive ability of this
algorithm in comparison with established criteria for LQTS
diagnosis.
Methods: A sample of 56 LQTS patients was selected from relatives
of confirmed LQTS probands who attended screening at the Mater
Misericordiae University Hospital Family Heart Screening Clinic.
Data were collected on demographic, clinical and genetic parameters.
Three exercise test measurements were chosen: supine QTc, 1 min
recovery QTc (1mQTc) and 4 min recovery QTc (4mQTc), Original
published cut offs (in ms) were used: QTc C 470 (males) QTc C 480
(females) for supine QTc, QTc C 426 for 1mQTc and QTc C 445 for
4mQTc. Area under the receiver operator characteristic (AUROC)
curves were used to describe the discriminative ability in the LQTS
gene positive group (n = 31), compared with the phenotype-negative
comparator group (n = 15).
Results: LQTS1 (n = 8), LQTS2 (n = 13) and LQTS3 (n = 10)
patients were included. Overall, the 4mQTc performed best in pre-
dicting LQTS gene status versus the comparator group, achieving
77.4 % sensitivity, 75.0 % specificity and an AUROC of 0.76 (95 %
CI 0.61–0.91). The Schwartz 1985 criteria achieved a similarly high
sensitivity and specificity at 77.8 and 66.7 % respectively with an
AUROC of 0.72 (95 % CI 0.58–0.86). 4mQTc correctly classified
100 % of LQTS1 patients and 84.6 % of LQTS2 patients. 4mQTc
was less reliable in LQTS3, with only 50 % sensitivity and 75.0 %
specificity.
Conclusions: Our results show that the new exercise test measure-
ments may be as useful as current diagnostic criteria for LQTS
diagnosis. 4mQTc is particularly helpful in diagnosing LQTS1 and
LQTS2 patients, but not LQTS3. This test can be a useful adjunct in
screening relatives of LQTS probands.
20. Frequent Premature Atrial Contractions are
Associated with Increased Mortality and Recurrent
Stroke Following Ischaemic Stroke/TIA
1Keaney JJ, 2Akijian L, 1Mulholland D, 2Nı´ Chro´inı´n D, 2Hannon N,
2Sheehan O, 1McGorrian C, 1Blake G, 1Mahon N, 3Kyne L,
3Duggan J, 2,3,4, Murphy S, 2Kelly PJ
1Cardiology Department, Mater Misericordiae Hospital, Dublin,
Ireland; 2Department of Stroke, Mater Misericordiae University
Hospital, Dublin, Ireland; 3Medicine for the Elderly, Mater
Misericordiae University Hospital, Dublin, Ireland; 4Royal College of
Surgeons in Ireland, Dublin, Ireland
Background: Following ischaemic stroke or transient ischaemic
attack (TIA) aggressive risk factor modification is undertaken to
reduce recurrent events. Atrial Fibrillation (AF) is a strong risk factor
for recurrent events. Frequent Premature Atrial Contractions (PACs)
on 24-hour ambulatory (holter) monitors are associated with the
subsequent development of AF.
Objective: We aimed to determine whether frequent PACs on holter
monitors were associated with a primary endpoint of death or
recurrent cerebrovascular events post stroke/TIA.
Methods: The North Dublin Population Stroke Study (NDPSS) 1 was
a prospective cohort study of patients with stroke/TIA in 2005 and
2006. Analysis was carried out of holter monitors of patients in this
study. Frequent PACs were defined as a rate of PACs C100 per 24 h.
Telephone interview and medical chart review was used to determine
recurrent events. The primary endpoint was all cause mortality or
recurrent stroke/TIA.
Results: Follow-up was achieved in 76 cases (61.8 % male). Mean
age was 69.3 ± 12.7 years. There were 18 recurrent events and 47
deaths. Kaplan–Meier event free survival demonstrated that patients
within the frequent PACs group had significantly poorer outcomes.
The primary endpoint occurred in 15 out of 18 patients in the frequent
PACs cohort versus 27 out of 54 (p = 0.004, logrank test). The
Hazard ratio for the primary outcome was 2.91 (95 % Confidence
Intervals 1.28–6.64) for those with greater than 100 PACs on the
holter. Median event free survival was 623 vs 2572 days. Multiple
regression analysis revealed that the effect was independent of age,
gender, hypertension and diabetes. Assessing the mortality and
recurrent CVA/TIA rates individually, the frequent PAC cohort had
also a significantly poorer rate of survival free from recurrent events
(p \ 0.05, logrank test) and mortality (p = 0.0005, logrank test).
Conclusion: Patients with a greater than 100 PACs per 24 h on holter
monitors following stroke/TIA are at a significantly increased risk of
death and recurrent cerebrovascular events compared with those with
fewer PACs.
21. Pulse Width Optimisation of ICD Defibrillation
Waveform is both a Safe and Effective Programming
Strategy at Time of Implant
Nolan PG, McFadden C, MacNeill BD, Crowley J, Nash PJ, Daly K
University College Hospital, Galway, Ireland
Introduction: Pulse width optimisation of ICD defibrillation waveforms
has been proposed as a means of reducing defibrillation thresholds.
The aim of this study was to assess whether pulse width optimisation
based on the high voltage lead integrity (HVLI) measurement is a safe
and effective. The HVLI measurement can also vary from the shock
lead impedance (SLI) measured during shock delivery. The study also
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aimed to investigate whether programming based on the HVLI would
be different from that based on the SLI.
Methods: Patients with SJM ICD’s, undergoing DFT testing, were
enrolled. The HVLI was checked and the defibrillation waveform pulse
width was optimised to Block 1 based on this. If a safety margin[10J
was not achieved DFT was reperformed using Block 2 and subsequently
Block 3 if required. SLI associated with shock delivery was noted.
Results: 102 patients, (m = 81.4 %, f = 18.6 %), mean age at
implant of 60.5 years (27.2–80.0 years) were enrolled. 73.5 % were
primary prevention and 26.5 % secondary prevention. Secondary
prevention patients had a mean EF of 32.8 %, and the mean EF was
22.8 % in the prophylactic group.
95.1 % of patients achieved an adequate DFT safety margin using
block 1 with a mean safety margin of 12.24J, 1.96 % were optimised
to Block 2 with a mean safety margin of 10.2J and Block 3 was used
in 2.94 % with a mean safety margin of 9.33J.
No significant difference between the HVLI and SLI (62.2 vs 65.19X,
p = 0.113) or programming of the waveform based on the HVLI or
the SLI was seen, either in Phase I (4.63 vs 4.75 ms, p = 0.09) or in
Phase II (3.01 vs 2.97 ms, p = 0.13).
During a mean follow-up of 2.97 years, 13 patients had episodes of
VF, defibrillated with first shock success.
Conclusion: Pulse width optimisation of ICD defibrillation wave-
forms is a safe and effective strategy at time of implant.
Session: Structural Heart Disease
22. Is Valve Choice the Main Determinant
of Paravalvular Leak Post Transcatheter Aortic Valve
Implantation?
Gough A, O’Sullivan K, Barry M, Hurley J, Sugrue D
Mater Misericordiae University Hospital, Dublin, Ireland
Background: Significant paravalvular regurgitation (PVR) following
transcatheter aortic valve implantation (TAVI) is associated with poor
survival. Unfavourable anatomic and pathological factors contribute.
There is considerable variability in PVR rates reported. The two most
popular valve delivery systems, Medtronic Corevalve (MCV) and Edwards
Sapien (ES), differ significantly in structure and deployment technique.
Methods: A systematic review of literature looking at PVR at time-
points up to 1 year, using different valve types was performed through
Pubmed and bibliographic searches from 2008–2013. One analysis
consisted of immediate, post-procedure and 30 day rates of PVR with
6 months and 1 year separately reviewed. A systematic review and
meta-analysis of studies of PVR in MCV and ES was performed.
Results: Over 8000 patients from over 20 studies looking at PVR up to
1 year were examined; focusing on 9 studies comparing MCV versus
ES outcomes, and other factors predisposing to PVR to ascertain if
valve choice is the main determinant of PVR. Pooled rate of significant
PVR was 9.0 % (95 % confidence interval: 5.5, 13.0). Rates at
6 months and 1 year were 10.2 % (95 % CI: 1.5, 24.9) and 7.0 % (95 %
CI: 0, 26.5) respectively. Examining valve types; MCV displayed more
PVR; 15.75 % [95 % CI 12.48–19.32] versus ES 3.93 % [95 % CI
1.05–8.38]. Comparing PVR rates by mixed-effects meta-regression
with fixed-effect moderator variable for valve type, suggesting statis-
tically significant difference in PVR rates between valves (p = 0.0002).
Conclusion: Approximately 10 % of patients develop PVR post
TAVI, impacting on survival. There’s no universally accepted method
of reporting rates of PVR between studies which would be useful to
ensure consistency in reporting. Numerous factors including valve
choice impact on PVR. Evidence suggests that valve choice remains
the most modifiable factor in reducing PVR post TAVI.
23. Renal Sympathetic Denervation Improves
Nocturnal Dipping in Hypertensive Patients
Tuohy S, Ryan L, Gleeson J, MacNeill B, Nash P, Daly K, Crowley J,
Sharif F
University College Hospital Galway, Galway, Ireland
Aims: Renal sympathetic denervation is an emerging device based
treatment for patients with resistant hypertension and has been shown
to reduce blood pressure in this group.1 Nocturnal Dipping is a
phenomenon where a decrease in blood pressure of 10 % or more
occurs during sleep. Nocturnal dipping has been shown to be pro-
tective against cerebrovascular and cardiovascular disease.2 There is a
paucity of data on the effect of renal sympathetic denervation on the
circadian rhythm of blood pressure. This study aimed to assess the
effect of renal sympathetic denervation on the 24 h blood pressure
profile of patients with resistant hypertension.
Methods and Results: Patients with resistant hypertension scheduled
for renal denervation in a single centre were included. All patients
underwent bilateral renal artery ablations using the SymplicityTM renal
denervation system. 24 h ambulatory blood pressure monitors were
given to patients prior to the procedure and at 9 months post procedure.
Software was used to calculate the degree of systolic, diastolic and mean
arterial pressure dipping nocturnally. 12 patients had complete 9 month
follow up at the time of this submission. At baseline, 5 patients (42 %)
were diastolic nocturnal dippers and 3 (25 %) were systolic nocturnal
dippers. 24 h ambulatory blood pressure monitors showed an overall
decrease of 5 mmHg systolic and 5.5 mmHg diastolic despite a
reduction in number of antihypertensive medications by over 20 %.
Both systolic and diastolic nocturnal dipping improved significantly.
Systolic dip increased by 6 mmHg (3 %) at 9 months post procedure
(paired samples t-test p = 0.002). Diastolic dip increased by 5.6 mmHg
(6 %) at 9 months post procedure (paired samples t-test p = 0.022). Of
the 7 patients that were classified as diastolic non-dippers at baseline, 4
patients (57 %) became diastolic nocturnal dippers.
Conclusions: Renal sympathetic denervation is an effective method
for management of resistant hypertension. An increase in systolic and
diastolic nocturnal dipping was noted in this study. This effect may
have additional cardiovascular benefits to the previously noted
reduction in blood pressure with renal sympathetic denervation.
References: [1] The Symplicity HTN-2 Trial): Lancet 2010 Dec 4;
376(9756):1903–92 Hypertens Res. 2010 Jul; 33(7):652–6
24. Sutureless Aortic Valve Replacement: A Rapid
Deployment, Minimally Invasive Alternative in Surgical
Aortic Valve Replacement
O’ Sullivan KE, Murphy A, Casserley I, Sugrue D, Hurley J
Mater Misericordiae University Hospital, Dublin, Ireland
Introduction: A new class of rapid-deployment aortic valves has
emerged with the potential to simplify minimally invasive aortic
valve replacement. Sutureless aortic valves have the potential to
shorten cross-clamp and cardiopulmonary bypass times in both
minimally invasive valve-only surgery as well as valve replacement
with concomitant procedures. We present a single-centre case series
using the EDWARDS INTUITY Valve System (Edward Lifesciences
LLC, Irvine, Calif) in the surgical management of severe aortic ste-
nosis to assess feasibility and efficacy in patients with high operative
risk.
Methods and Results: Valve implantation using the INTUITY valve
was successfully performed in seven patients (4 men, 3 women, mean
age 78.7 ± 12.9). Average cross-clamp time was 51 ± 20 min,
S376 Ir J Med Sci (2013) 182 (Suppl 8):S359–S392
123
average cardiopulmonary bypass time was 72 ± 23. Four patients
underwent aortic valve replacement only, three of which were per-
formed via mini-sternotomy. Three patients underwent concomitant
coronary artery bypass grafting also. Death, major cardiac or cere-
brovascular events did not occur. Two post-operative complications
occurred; a lower respiratory tract infection and re-intubation in a
heavy smoker. Average hospital stay was 9 ± 3 days. Post procedure
echocardiography confirmed excellent valve haemodynamics in all
patients.
Conclusions: Surgical aortic valve replacement using the
EDWARDS INTUITY Valve System is a feasible alternative in our
experience thus far. Reduced aortic cross-clamp and cardiopulmonary
bypass times are likely to result in improved patient outcomes in
larger patient cohorts. Early haemodynamic performance indicates
excellent results and the system facilitates a minimally invasive
approach. This approach is likely to yield additional patient benefits
although further studies are required to clarify.
25. Resection of Renal Cell Carcinoma Extending
into The Heart: Avoidance of Deep Hypothermic
Circulatory Arrest
McBride M
Royal Victoria Hospital, Belfast, Ireland
Background: The management of primary renal cell carcinoma
(RCC) with cavo-atrial tumour/thrombus extension is challenging.
Operative resection remains the cornerstone of treatment. Debate
exists regarding the optimal surgical strategy. Deep hypothermic
circulatory arrest (DHCA) is often used to provide a bloodless
surgical field but is associated with significant morbidity and
mortality. We explored a simplified approach using low flow car-
diopulmonary bypass (CPB) with the heart beating, avoiding
DHCA.
Methods: From June 2003 to April 2013, 11 patients with pri-
mary RCC extending into the vena cava, right atrium, or both,
underwent radical nephrectomy and cavo-atrial thrombectomy. CPB
was established with venous drainage from both the superior vena
cava and infra-renal IVC (or femoral vein). Once kidney was
mobilized, flow was reduced under conditions of moderate hypo-
thermia and the cava and right atrium were opened, with the heart
beating, to extract the tumour. Additional procedures included
CABG X 3 (n = 1), closure of atrial septal defect (n = 1) and
pulmonary embolectomy (n = 1). The mean age of patients was
57 years (range 36–70), 7 were male.
Results: Complete tumour resection was achieved in all cases. Mean
CPB time 98 min (67–141 min). In no case was DHCA used. Mean
number of blood transfusions was 21 (5–57). In hospital 30-day
mortality was 0 %. Mean follow up was 43 months (1–119 months).
Survival at 1-year was 70 %. Mean survival 31 months
(1–119 months). Survival at 2 and 5-years 37.5 and 20 % respec-
tively. 6 patients are still alive. Of the 5 deceased, 3 died due to
recurrent metastatic disease.
Conclusion: RCC with cavo-atrial tumour-thrombus involvement can
be simply and safely operated on with the use of adjunct low flow
CPB with modest hypothermia. This avoids the deleterious effects of
DHCA and is associated with favourable short and long-term survival
outcomes.
26. Can Low Volume Adult Congenital Surgery be
Delivered Safely in a High Volume Adult Cardiac
Surgery Unit?
Austin CR, Wood AE, Graham ANJ
Royal Victoria Hospital, Belfast
Objective: Within the UK there is a review of Adult Congenital Heart
Disease Services. This has stem from the Bristol Inquiry, Kennedy
Report, Surgery for Children: Delivering a First Class Service by
Royal College of Surgeon England and then Safe and Sustainable
Review. The recommendation is high volume units performing adult
congenital surgery. We feel that we have achieved this result due to
our frame work within a small volume unit.
Method: Data was collected prospectively from April 2010 to March
2013. This data was entered into a data base called Heart Suite. Data
from our unit was compared to Data from CCAD and SCTS.
Results: Ninety adults were assessed with age ranging from 16 to
75 years and average age of 37 years. There were twenty different
operations ranging in different complexity. Each case was risk strati-
fied by STS-EACTS category ranging from category 1 to 4. There was
no recorded mortality in this group of patients. This data was validated
to up to 2012 by CCAD group. We perform on average about 30 cases
per year. When compared the other 26 units performing Adult Con-
genital Surgery in the UK average number of cases 38.5 with a median
of 20.6. From the SCTS Data April 2008 to March 2011 Royal Victoria
Hospital has performed 2,534 case (Average 845/yr) and April 2011 to
March 2013 approximately over 1000 cases year.
Conclusion: Adult Congenital Cardiac Surgery with low volume can
be performed in a high volume Adult Cardiac Surgical Unit safely as
demonstrated with our results. Ongoing Clinical governance and
Multi-disciplinary approach is vital to our ongoing surgical outcomes.
27. The St Jude TrifectaTM Aortic Valve: Early Clinical
Experience from a Single Centre in the West of Ireland
McVeigh TP, Keita L, Steter D, O’Connor M, Blach A, Kolcow W,
Veerasingam D
West of Ireland Cardiothoracic Unit, Galway University Hospital,
Galway, Ireland
Objectives: The St. Jude Medical Inc. Trifecta TM valve is a new
stented bio-prosthetic aortic valve designed to have a large effective
orifice area with low post-operative echo gradients. We aimed to
investigate the outcomes of aortic valve replacement (AVR) using the
Trifecta TM valve in a series of patients in the west of Ireland.
Methods: A longitudinal cohort study was undertaken. Data was
obtained from a prospectively-maintained electronic patient record sys-
tem. We included all patients undergoing AVR utilizing the St. Jude
TrifectaTM valve over a period between March 2011 and November 2012.
Data was tabulated with respect to patient characteristics, valve size and
External Orifice Area Indices (EOAIs) as well as pre- and post-operative
echocardiographic parameters. Data was analysed using SPSS v.19.
Results: Thirty-eight patients were included in this series, comprising
27 (71 %) males and 11 (29 %) female patients. The median age of
the cohort was 73 years (range 26–87), with no difference between
genders. The majority of patients were referred for AVR because of
symptomatic or severe asymptomatic Aortic Stenosis (n = 32, 84 %),
while 4 (11 %) patients had symptomatic Aortic Regurgitation, and 2
(5 %) had mixed pathology. Two patients were referred for emergent
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repair because of infective endocarditis. The median Euroscore in this
group was 9. Post-operatively there were significant improvements in
both mean (47 ± 19 mmHg –v- 9 ± 4 mmHg, p \ 0.0001 (paired
samples t test)) and maximal (74 ± 29 mmHg –v- 17 ± 8 mmHg,
p \ 0.0001) pressure gradients. There was also a significant reduction
in pro-BNP levels following surgery (p = 0.036, Wilcoxon Signed
Rank Test), and in levels of diastolic dysfunction (p = 0.047, X2).
The median EOAI achieved was 0.91 (range 0.78–1.26).
Conclusion: The early experience of TrifectaTM aortic valve in our
institution is promising, with significant reductions in post-operative
pro-BNP levels, pressure gradients and diastolic dysfunction, even in
high-risk patients. Long-term results of durability are awaited.
28. Clinical Outcomes of Trans-Catheter Aortic Valve
Replacement at a Tertiary Cardiac Centre in Ireland
Neylon A, Casserly I, Sugrue D, Hurley J, Blake G, McGorrian C,
Moran B, McAdam B, Foley D, Diamond P
Mater Misericordiae University Hospital, Dublin, Ireland
Background: Percutaneous aortic valve replacement (TAVR) is an
emerging technology that is approved for the treatment of patients
with severe symptomatic aortic stenosis who are at high or prohibitive
risk for surgical valve replacement. We sought to assess the clinical
outcomes of patients treated with TAVR at our institution.
Methods: All patients undergoing TAVI at the MMUH and MPH
hospitals from the initiation of the program in November 2008 to the
current date were identified. A prospective TAVI database utilizing
the data elements from the STS/ACC TVT registry was established in
June 2012 to collect data. For patients treated prior to that date,
retrospective review of the medical record was performed to populate
the data elements.
Results: A total of 64 patients underwent TAVR, with the majority
being male (n = 42. 65 %) The mean age of the cohort was
83±4 years. The majority of patients were treated using the transfe-
moral route (n = 48, 75 %), using the Edwards Sapien XT valve
(n = 62, 97 %). There were a total of 15 deaths and 3 major strokes
in the cohort. The Kaplan–Meier estimate for death/major stroke at
1 year was 72 % (CI 56–82 %) (Figure below). The permanent
pacemaker rate was low (n = 3, 5 %).
Conclusions: The clinical outcomes of TAVR observed at this ter-
tiary cardiac center in Ireland appear reasonable compared to
outcomes reported from the PARTNERS trial. Continued refinement
of patient selection is required to optimize clinical outcomes and
efficient utilization of resources.
29. Atrial Septal Defect And Left Atrial Appendage
Closure: A Single Centre Experience
Ryan N, Mc Adam BF, Foley DP
Beaumont Hospital, Dublin, Ireland
Background: Transcatheter structural heart interventions for closure
of patent foramen ovale, atrial septal defects and left atrial appendage
occlusions are routinely carried out under general anaesthesia with a
minimum one night hospital stay. The Irish healthcare system is in
permanent crisis due to lack of inpatient beds. To increase availability
of interventional cardiac procedures, we instigated an ambulant care
day case approach to a wide range of interventional cardiac proce-
dures over a number of years.
Objectives: Compare day case transcatheter structural heart proce-
dure complications with published data. Demonstrate the safety of
day case procedures.
Methods: Retrospective review of all interventional heart procedures
over a fifteen-month period. All procedures are carried out under
conscious sedation and local anaesthesia with fluoroscopic guidance
and additional transoesophageal ECHO guidance for LAA occlusions
and ASD closures.
Results: Of 1446 planned day case cardiac interventions, 45 were
for structural heart procedures, 8 PFO, 8 ASD and 29 LAA closures.
The procedure was successful in 93.4 % of cases with 15.5 % of
patients requiring admission from the cardiology day ward. Two
patients were admitted as their procedures finished late in the day.
One patient was admitted post septal occlusion device embolization
with successful retrieval. Four patients were admitted post LAA
occlusion, two with pericardial effusions not requiring drainage, one
with femoral haematoma (14F sheath) and one for syncope (postural
hypotension). The majority (71.4 %) were discharged the following
day. There were no readmissions within 30 days, 2 (4.4 %) patients
attended the ED.
Conclusion: Most common transcatheter TOE guided structural heart
procedures can be safely planned and carried out as day procedures
under conscious sedation. A small minority of patients required
admission with the majority being discharged the following day. Our
periprocedural complication rate is in keeping with the published
literature. A small minority of patients requiring admission, the
majority being discharged the following day.
30. Second Generation Left Atrial Occlusion Devices:
A Single Centre Experience
Canniffe C, Neylon A, McCann C, Casserly I, Walsh K
Mater Misericordiae University Hospital, Dublin, Ireland
Atrial fibrillation (AF) is associated with up to 33 % of strokes in
Ireland. Anticoagulation is the only therapy that has been shown to
reduce mortality and stroke risk in patients with AF, however it is
estimated that up to 50 % of those who meet criteria for anticoagu-
lation do not receive it.
Percutaneous left atrial appendage occlusion (LAAO) has been shown
to be non-inferior to Warfarin therapy in terms of stroke prevention.
However adverse event rates relating to implantation, including
stroke, thrombus formation and pericardial effusion, have been esti-
mated to occur in up to 4.1 % of implants.
Second generation LAAO devices (Amulet) are now available.
Design features include a longer lobe and larger disc diameters to
improve coverage of the appendage and an end-screw that is flush with
the device disc to reduce the possibility of device associated thrombus.
We report our experience with this second generation device.
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To date we have implanted Amulet devices in 8 patients. All had a
history of persistent AF. 62.5 % of patients reported a history of
bleeding- this occurred on Warfarin in 60 %, and on a novel oral
anticoagulant in 40 %.
Median size of device implanted was 24 mm (22–31 range). Four
procedures were done in conjunction with a pulmonary vein isolation.
One was done in conjunction with an atrial septal defect closure, one
with an ICD box change. Two were individual procedures. Mean
radiation screening time was 24.7 min.
All devices were successfully implanted. No acute peri-procedural
complications were recorded. 50 % of patients have had a transo-
esophageal echocardiogram since LAAO implantation- with no
thrombus or significant residual left atrial appendage flow identified.
Conclusion: In this small series, left atrial appendage occlusion with
Amulet devices is shown to be effective with an excellent safety profile.
31. Prevalence of Pacemaker Requirement Post
Medtronic Corevalve Implantation
Noad R L, Manoharan G, Spence MS
Belfast Health and Social Care Trust, Belfast, NI
Introduction: Pacemaker requirement is a known complication of
Transcatheter Aortic Valve Implantation (TAVI), the incidence of
which is reportedly higher with CoreValve implantation. We sought
to assess the prevalence of pacemaker requirement at our centre, the
utilisation of pacing and examine predictors pacemaker requirement.
Methods: Our TAVI database was analysed and data obtained on patients
who required pacemaker implantation post-CoreValve implant, and a
randomly selected group of patients who did not require a pacemaker.
Results: In total 44 patients received a pacemaker post-CoreValve.
Overall 30-day post procedure pacemaker rate was 27.8 %, this
decreased from 28.5 % to 22.6 % between 2008–2012. Implanted
pacemakers on average utilised atrial pacing 27.5 % and ventricular
pacing 86.7 %. Predictors included degree of valve calcification,
length of PR and QRS interval, AV block intra-procedurally and
depth of CoreValve (Table 1). There was no significant difference
in one-year mortality between the two groups (p = 0.550).
Conclusions: Belfast pacemaker implant rate post-TAVI is compara-
ble with other international centres. Rate of pacemaker implant are
falling possibly due to improvements in technique and patient selection.
32. Audit of Safety and Efficacy Outcomes of Patients
Undergoing Left Atrial Box Isolation for Atrial
Fibrillation
O’Neill L, Hensey M, Keane D
St. Vincent’s University Hospital, Dublin, Ireland
Background: Isolation of the pulmonary veins alone (PVI) is asso-
ciated with a 50–70 % clinical success rate in paroxysmal atrial
fibrillation but is significantly lower for persistent atrial fibrillation.
More comprehensive ablative strategies have evolved that may offer
higher success rates. Posterior left atrial box isolation is one such
technique for which there is only limited and conflicting data with
regard to its safety and efficacy.
Methods: We performed an audit of 100 patients undergoing LA box
isolation over the last 4 years. Recurrence of arrhythmia was detected
by evaluating symptoms and continuous 24 h ECG monitoring at 2, 6
and 12 months post procedure.
Results: The average age of the group was 55.6 ± 9.5 years. Average
duration of atrial fibrillation was 5.4 ± 5.2 years. Persistent atrial
fibrillation was present in 71 %. Left atrial enlargement was docu-
mented in 43. All had been on at least one anti arrhythmic medication.
Patients underwent circumferential PVI plus linear posterior LA lines
to complete box isolation. Complete LA box isolation was achieved
in 99 %. At a mean follow up of 11.2 ± 5.1 months 73 patients were
free from atrial fibrillation. 53 % were taking no anti arrhythmic
Patient Characteristics
(N = 8)
Age, years (mean, range) 65.4 (49–78)
Male (%) 75
CHADSVacs Score (mean) 2.1
HAS-BLED Score (mean) 2.2









Age 81.0±7.4 80.5±6.7 p=0.765
Male(%) 17(39.5) 23(52.3) p=0.786
Aortic valve area 0.76±0.45 0.70±0.55 p=0.487
Corevalve size
• 23 1(2.3) 0(0) p=0.220









• 29 22(51.2) 18(38.3)
• 31 9(20.9) 8(17.0)




• 1 18(41.9%) 20(45.5%)
• 2 8(18.6%) 16 36.4)
• 3 p=0.056
Pre-op rhythm(%)
• Sinus 32(74.4) 26(59.1) p=0.260
• Atrial fib/flutter 11(25.6) 18 40.1)
Valve Depth 5.6 7.0 p=0.020





Pre-op LAD 1(2.3) 8(17.0) p=0.032
Pre-op BBB(%)
• RBBB 8(18.6) 11(25) p=0.233
• LBBB 8(18.6) 4(9.1) p=0.220
Pre-op QRS interval 99.3 ± 18.5 115.0 ±
25.4
p=0.001
New LBBB 23(53.5) 17(39.5) p=0.152
AV block intra-procedurally 0(0) 10(22.7) p=0.003
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medication. Five of this group developed clinically significant atrial
flutter. Twenty-six patients had recurrence of atrial fibrillation, 72 %
of which had previous persistent AF. Recurrence was paroxysmal in
61.5 %. Fifteen patients underwent repeat procedures. There were no
adverse events relating to the procedure.
Conclusion: This provisional data on clinical efficacy and safety from
a single series would suggest that a strategy of left atrial box isolation
is worthy of further evaluation in a multicentre registry.
33.Why Do Patients With Bicuspid Aortic Valve
Undergo Surgery?
Canniffe C, Neylon A, O’Neill JO, Nolke L, Redmond M, McCarthy J,
Walsh K. Mater
Mata Misericordiae University Hospital, Dublin, Ireland
Purpose: To determine the indications for surgical intervention in
patients with bicuspid aortic valves (BAV) at a tertiary centre and to
document the short term outcomes of such interventions.
Methods: A retrospective review of (i) our adult congenital heart
database and (ii) patients with a diagnosis of BAV who were referred
to a tertiary cardiology and cardiothoracic centre between 2000–2012.
Results: To date 613 patients with a diagnosis of BAV have been
identified. Of these, 47.5 % had surgery, at a mean age of 52.9 years
(±19.1 years). The commonest primary indication for surgery was
aortic stenosis (AS, 53 %). Other primary indications for surgical
intervention included aortic root dilatation (13 %), aortic regurgita-
tion (8.3 %), endocarditis (5 %), mixed aortic valve (3.4 %) and
aortic dissection (0.4 %). 30 day mortality following surgical inter-
vention was 0.9 %. Total survival was 95.1 % at a mean follow up of
2.79 years. Of the survivors, 4.6 % required a re-do procedure during
follow up. The commonest indication for a re-do procedure was aortic
regurgitation- accounting for 36.8 % of such procedures.
Conclusions: Patients with congenitally bicuspid aortic valves referred
to tertiary centres have a high rate of surgical intervention. The com-
monest indication for intervention is aortic stenosis. 30 day mortality
rates and need for re-do surgical intervention were low in our series.
34. Is Post-Mortem Evaluation of Cardiac Rhythm
Management Devices Useful?
Nolan PG, Hynes S, Tuohy S, Macneill BD, Nash PJ, Crowley J,
Daly K
Galway University College Hospital, Galway, Ireland
Introduction: The number of implanted cardiac rhythm devices is
increasing. Overall little data exists on the rate, feasibility and
information garnered from device interrogation post mortem.
The aim of the study was to investigate whether device interrogation
provided additional information for the pathologist and whether
device function was normal.
Methods: Devices were explanted from 32 consecutive post mortem,
between 2008 and 2011, and were interrogated. Interrogation and
interpretation of the device data was performed blinded to the post-
mortem findings. Battery voltage, charge time, lead impedances,
thresholds and intrinsic amplitude measurements were recorded. Data
related to potential arrhythmias was also recorded, as was pacemaker
dependency, defined as pacing [80 %. After data collation the
investigators jointly decided as to the value of the interrogation on a
case by case basis.
Results: 24 pacemakers and 8 ICD’s were studied. The mean age of
patients at time of death was 75 (range 31.8–95) years and the device
had been implanted for a mean of 3.2 (range 0–9.6) years.
There was an advisory on 3 ICDs and 1 ICD lead but they demon-
strated normal function.
Device measurements were normal for all devices.
High ventricular rates were recorded in 9/24 cases, three occurring on
the date of death. Device data and cause of death concurred in 9 cases.
It was discordant in 4 cases, 3 of these devices did not have EGM
storage capability and reported cause of death was fatal arrhythmia. In
the fourth no high rates were recorded although a VF arrest was
documented.
2/8 ICD interrogations concurred with cause of death. However 3
were discordant, interrogation revealing no arrhythmia, reported
cause of death being fatal arrhythmia, suggesting asystole or PEA as
the potential fatal arrhythmia.
Conclusion: Post-mortem device interrogation is feasible, providing
additional information in 14/32 cases with concordance with cause of
death in 11/32.
35. Implantable Cardioverter-Defibrillators in Heart
Transplant Recipients: A Single Centre Experience
Neylon A, Canniffe C, Parlon B, Egan J, McCarthy J,
Mahon N, O’Neill JO
Mater Misericordiae University Hospital, Dublin, Ireland
Purpose: Graft vasculopathy with or without left ventricular dys-
function may act as a substrate for arrhythmic death in patients
following remote orthotopic heart transplant (OHT). The role of
implantable cardioverter-defibrillators (ICD) for the prevention of
sudden cardiac death (SCD) in these patients is unclear. We examined
the use of ICDs in adult OHT recipients in a single transplant centre.
Methods: We analysed the records of OHT recipients who had an
ICD implanted. Details on patient demographics, time from OHT,
indication for ICD, presence and severity of graft vasculopathy, left
ventricular ejection fraction (LVEF), device therapy delivered and
complications associated with ICD insertion were collected.
Results: A total of 296 transplants were performed from 1985 to 2012,
of whom 9 (3.3 %) had an ICD implanted post transplant. Of ICD
recipients, the average age at transplant was 39 years (±14.2 years),
and 7/9 (77 %) were male. Mean time from OHT to ICD was
16 ± 6 years. Defibrillation threshold testing (DFT) was performed in
6/9 (66.6 %). The indications for ICD implantation were as follows:
severe graft vasculopathy in 5, LV dysfunction with moderate graft
vasculopathy in 1, sustained ventricular tachycardia in 2 and moderate
graft vasculopathy with high grade AV block on exertion in 1. Two
patients had experienced syncopal episodes. In those with severe graft
Patient Characteristics BAV Patients who underwent
surgical intervention
(mean, SD)
Age (years) 47.6 (17.8)
Male (%) 69.9
Hypertension (%) 28.1




Prior diagnosis of aortic
coarctation (%)
19.3
S380 Ir J Med Sci (2013) 182 (Suppl 8):S359–S392
123
vasculopathy the average LVEF was 57 % (±7 %). The average fol-
low-up after device implant was 10 months (±7 months). One patient
had successful anti-tachycardia pacing (ATP) for ventricular tachy-
cardia 13 months post implant. One patient died of SCD (DFT tested
after implant) and subsequent device interrogation revealed ventricu-
lar fibrillation followed by electromechanical dissociation. To date
there have been no complications associated with ICD insertion.
Conclusions: The use of ICDs for the prevention of SCD in patients
with remote OHT remains unproven and the subject of ongoing
analysis. Routine testing of DFTs at the time of implantation in
patients may not be appropriate
36. Cost-Effective Bridging to Cardiac Transplantation:
A Future For Ventricular Assist Devices?
Tracey C, Lawler Z, O’Neill JO, McCarthy J, Egan J, Mahon NG
Mater Misericordiae University Hospital, Dublin, Ireland
Background: Because of improved heart failure treatments, the
profile of patients listed for cardiac transplantation has changed sig-
nificantly over the past 2 decades. Specifically patients have more
advanced disease, greater degrees of renal impairment and pulmonary
hypertension, and a higher dependence on continuous inotropic
therapy or other forms of ventricular support. Concomitantly, tech-
nologic advances have greatly improved outcomes of ventricular
assist devices (VAD) as bridges to transplantation (BTT). Accord-
ingly, early VAD implantation may be more cost effective than a
default strategy of support with inotropes or intra-aortic balloon
counter-pulsation (IABP).
Aim: To determine the hospital cost of bridging patients to cardiac
transplantation by continuous inotrope infusion ± IABP.
Methods: Two representative patients were selected, one inotrope-
dependent, the other on IABP. Detailed cost analysis was performed,
including length of stay (LOS) prior to transplant, bed-day costs, costs
of peripherally inserted central catheters and of IABP. Patients sup-
ported to transplant in hospital on inotrope/IABP 2006–2013 identified
from transplant database together with their pre-transplant LOS.
Results: Total cost patient 1 (IABP, LOS 370 days): €565,960. Total
cost patient 2 (inotrope, LOS 292 days): €380,750. Between 2006 and
2013, 15 patients were supported predominantly with IABP, mean
98 days (14–390), 66 % male, mean age 45 (16–65); 14 patients were
supported predominantly with inotropes, mean 178 days (34–400),
90 % male, mean age 43 (17–54); 2 patients were supported with both
consecutively (inotrope then IABP) (182 days + 31 days and
64 days + 30 days respectively).
Nine patients (29 %) eventually underwent VAD implantation as BTT
(mean time to VAD = 86 days (20–400)). Twenty of these patients
(67 %) transplanted to date; 5 (16 %) have died awaiting transplantation.
Total cost of bridging to transplant or VAD for this cohort = €5,366,400.
Conclusion: Bridging inotrope or balloon-pump dependent patients
to transplantation is expensive, warranting exploration of alternative
strategies. For patients dependent on IABP, comprising more than
50 % of this cohort, a default strategy of early VAD implantation may
prove cost effective.
37. An Audit of the Prescription of Clopidogrel
with Reference to Duration of Therapy and Instructions
for Use
1Sutton-Fitzpatrick U, 2Natin S. 2Reilly D
1University of Limerick, Limerick, Ireland, 2General Practice,
Limerick, Ireland
Introduction: Clopidogrel is a commonly prescribed anti-platelet
agent. Its indications include coronary artery disease, post-stent
insertion, peripheral vascular disease and prophylaxis post-cerebro-
vascular accident (CVA). Clear guidelines on the optimum duration
of clopidogrel therapy are scarce. NHS guidelines advise a maximum
12 months prescription following acute coronary syndrome (ACS) or
stent insertion. These guidelines also state that clear instructions be
given to the primary care team at the time of initial prescribing.
Purpose: To determine how long patients have been on clopidogrel,
and if this is in accordance with current recommendations whether clear
instructions were given at the time of initial prescribing as to duration of
therapy and if patients were reviewed if instructions were adhered to.
Methods: An audit of 50 patients in a general practice setting who
had been prescribed clopidogrel in the three year period, January 2010
to January 2013. Data were obtained through the patients’ files using
the patient information programme Socrates.
Results: 76 % of all patients were prescribed clopidogrel for
ACS ± stenting with 92 % of these remaining on clopidogrel for over
1 year, 63 % for over 2 years and 13 % for over 5 years.
48 % of all patients on clopidogrel had no clear instructions regarding
duration of therapy at time of initial prescription. In 18 % there was
no record of initial discharge letter/prescribing note.
28 % of all patients on clopidogrel had further instructions from
outpatient reviews regarding duration of clopidogrel therapy.
Cardiology and GP services did not adhere to prescribing instructions
in 20 % and 16 % of patients respectively.
Conclusion: This audit highlights the variability of duration of
clopidogrel therapy and the need for clear prescribing instructions,
better reviews of patients on this drug, better inter-doctor communi-
cation and better prescribing guidelines.
Session: Young Investigator Award
38. Restoration of Platelet Function with Platelet
Transfusion in Acute Coronary Syndrome and Cardiac
Surgery Patients on Dual Antiplatelet Therapy-
the APTITUDE Study
O’Connor SA, Martin R, Amour J, Abtan J, Kerneis M, Silvain J,
Brugier D, Leprince Pascal, Montalescot G, Collet JP
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re
Hospital (AP-HP), Universite´ Paris 6, France
Background: The APTITUDE study was designed to demonstrate the
effect on restoration of platelet function of ex vivo (APTITUDE ACS/
PCI) and in vivo (APTITUDE BLEED) platelet transfusion (PT) in a
coronary populations treated with P2Y12 receptor antagonists.
Methods: In the APTITUDE ACS/PCI study, patients presenting
with ACS or for elective PCI, receiving a loading doses (LD) of one
of clopidogrel, prasugrel or ticagrelor were included. Platelet trans-
fusion (PT) was performed ex vivo by mixing platelet rich plasma
(PRP) from blood sampling performed before administration of LD in
increasing proportions with PRP sampled 4 h after LD. Light trans-
mission aggregometry (LTA) measuring residual platelet aggregation
(RPA) in response to 20 lmol/L adenosine diphosphate was assessed.
In the APTITUDE BLEED study, platelet function using several
laboratory techniques was assessed before and after in vivo PT
administered for excessive bleeding in patients undergoing cardiac
surgery treated with maintenance dose P2Y12 receptor antagonists.
Results: A total of 45 patients (76 % male, 50 % ACS) were included
in the APTITUDE ACS/PCI study including n = 13 clopidogrel
600 mg, n = 12 clopidogrel 900 mg, n = 10 prasugrel 60 mg and
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n = 10 ticagrelor 180 mg. The % restoration of platelet function
achieved with 80 % proportion PT (RPA 80 % PT mix/RPA Baseline
x 100) significantly decreased with increasing potency of P2Y12
inhibitor (83.9 ± 11 %, 73 ± 14 %, 66.3 ± 15 %, 40.9 ± 19 %
respectively; p for trend\0.0001). In APTITUDE BLEED, a total of
54 patients (67 % male) treated with aspirin and either clopidogrel
(n = 45), prasugrel (n = 6) or ticagrelor (n = 3) were included.
Compared to baseline there was a significant increase in platelet
activation, as assessed by vasodilator-stimulated phosphoprotein
platelet reactivity index (VASP-PRI) (42.1 ± 23.3 vs 53.3 ± 19.4 %;
p \ 0.0001) (Figure 2).
Conclusions: Platelet transfusion appears to lead a significant resto-
ration of platelet reactivity in patients treated by P2Y12 receptor
antagonists but has less efficacy with more potent agents.
Fig. 1 Platelet aggregation as
assessed by light transmission
aggregometry demonstrating
baseline values before loading
close (LD), 4 hours post LD and
after platelet transfusion ex vivo
with platelet rich plasma (PRP)
from baseline in ascending
proportions
Fig. 2 Platelet activation as
assessed by vasodilator-stimulated
phosphoprotein platelet reactivity
index (VASP PRI %) measured
before (T0) and after (T1) platelet
transfusion according to P2Y12
inhibitor
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39. Dynamic Surface ECG Markers of Arrhythmogenic
Right Ventricular Cardiomyopathy Patients
Undergoing Electrophysiology Studies
Sugrue A, Finlay MC, Lambiase PD
Institute of Cardiovascular Science, The Heart Hospital, University
College Hospital, University of London, UK
Background: Early (or concealed) ARVC disease has increased
predisposition to arrhythmias and SCD. Understanding and aiding
detection of concealed ARVC may help reduce this predisposition.
Aim: To examine how the myocardium in concealed ARVC dis-
ease behaves under the stress of imposed rapid and controlled heart
rates by the analyse of surface ECG parameters in EPS. Further-
more, to observe if these ECG parameters differ from RVOT and
controls.
Methods: 44 patients (22 ARVC—without evidence of right ven-
tricular myocardial disease, 9 RVOT, 13 Normal Controls) underwent
EPS with standardised pacing protocol involving S1 and S2 beats.
The follow ECG parameters were compared for S1 and S2 imposed
beats; QRS duration, T wave Duration (TWD), Latency Period
Duration (LPD), T wave peak to T wave end duration (Tpe) and QT
interval.
Results: Multivariate analysis identified significant differences in the
dynamic ECG parameters of the three groups (p = 0.008). For S1
beat; ARVC and RVOT patients had a statistically significantly
longer TWD when compared to controls (193.3 ms, 201.6 ms and
174.6 ms respectively, p = 0.005); as was Tpe duration (96.9 ms,
102.3 ms and 86.9 ms, respectively, p = 0.007). Post hoc confirmed
differences between ARVC vs Controls (TWD difference = 18.8 ms
p = 0.019, Tpe difference = 10.1 ms p = 0.0029) and RVOT vs
Controls (TWD difference = 27.0 ms, p = 0.005, Tpe differ-
ence = 15.46 ms, p = 0.005). The LPD of the S2 beat was
statistically different in all groups (54.63 ms—Controls, 54.67 ms—
RVOT, 72.30 ms—ARVC, p = 0.002). Discriminate analysis
enabled 66.7 % to be classified successfully (80 % ARVC, 69.2 %
Normal, 33.3 % RVOT).
Conclusion: Dynamic surface ECG changes occurred during EPS in
concealed ARVC disease. These dynamic changes enabled differen-
tiation of concealed ARVC from RVOT and normal myocardium.
Addition analysis suggests early ARVC may mimic RVOT.
40. The Effect of Multiple Micronutrient
Supplementation in Patients with Chronic Stable Heart
Failure: A Randomized, Placebo-Controlled Trial
1,3McKeag NA, 1McKinley MC, 1Woodside JV, 2,3Harbinson MT,
1,3McKeown PP
1Queen’s University, Centre for Public Health, Belfast, NI:
2Queen’s University, Centre for Vision and Vascular Science,
Belfast, NI: 3The Heart Centre, Belfast Health &Social Care Trust,
Belfast, NI
Background: The aim of this study was to investigate the effect of a
multiple micronutrient supplement (including vitamin D (50 mcg/d))
in patients with chronic stable heart failure (CHF).
Materials and Methods: This was a double-blind, placebo-con-
trolled randomized trial. Seventy-nine patients on optimal treatment
for CHF (left ventricular ejection fraction (LVEF) B45 %) were
randomized to receive a multiple micronutrient supplement or pla-
cebo. Endpoints were assessed at baseline and after 12 months. The
primary endpoint was LVEF, assessed using cardiac magnetic res-
onance imaging or 3-dimensional echocardiography. The secondary
endpoints were as follows: quality of life (Minnesota Living With
Heart Failure Questionnaire), physical functioning (6-minute walk
test distance), blood levels of N-terminal prohormone of brain
natriuretic peptide and markers of systemic inflammation (C-reactive
protein, tumour necrosis factor-alpha, interleukin-6, interleukin-10),
and levels of oxidative stress (urinary 8-iso-prostaglandin F2 alpha).
Compliance was assessed by measuring blood levels of vitamin D
and B6.
Results: Treatment with a multiple micronutrient supplement had no
significant effect on LVEF or any of the secondary endpoints. The
results for the primary endpoint and the blood levels of vitamin D and
B6 are summarized in the Table.
n Baseline 12 Month p
LVEF Active 33 38.9 (11.1) 38.6 (10.9) 0.441
Placebo 35 44.7 (8.8) 44.9 (12.0)
Vitamin D Active 34 38.7 (13.8) 99.6 (23.8) \0.001
Placebo 36 38.6 (23.7) 35.3 (22.0)
Vitamin B6 Active 35 56.4 (34.4) 106.9 (59.1) \0.001
Placebo 36 57.3 (26.6) 52.1 (27.0)
Results are presented as mean (standard deviation), p: significance
of difference between treatment groups (analysis of covariance).
Discussion: Despite evidence of good compliance with the inter-
vention in this group of patients with CHF, micronutrient
supplementation did not result in any significant changes in the pri-
mary or secondary endpoints.
41. Circulating Endothelial Cell Enriched Gene
Expression Analysis in Acute Myocardial
Infarction
Barrett PM, Topol EJ
Scripps Translational Science Institute, 3344 N. Torrey Pines Court,
Suite 300 La Jolla, CA 92037, USA
Background: Circulating endothelial cells (CECs) that line the cor-
onary artery endothelium are sloughed off during atherosclerotic
plaque rupture preceding myocardial infarction (MI). Comparison of
gene expression levels in these cells between those experiencing an
MI and healthy controls may determine the genes associated with the
deleterious CECs released during coronary artery atherosclerotic
plaque rupture.
Methods: Blood was collected from 21 MI patients and 22 age-
matched healthy donors. CECs were isolated using the CellSearch
system with the CellSearch CEC Profile kit. The total RNAs were
isolated from CECs according to standard Trizol method. 50 ng total
RNA was first converted to labeled target cDNA using the Ovation
RNA Amplification System V2. Subsequently, 3.75 lg of the puri-
fied cDNA underwent a two-step fragmentation and labeling process
using the Encore Biotin Module. Targets were hybridized to Af-
fymetrix human U133 Plus 2.0 array. Following hybridization, arrays
are washed and stained before scanning on the Affymetrix GeneChip
Scanner and data extracted using Expression Console. Using the first
12 myocardial infarction subjects and 13 healthy age matched con-
trols a database containing a training collection of approximately
54,000 expression patterns was created. Principal components (PC)
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analyses of the CEC gene expression profiles were used to dis-
criminate myocardial infarction subjects from healthy controls.
Estimation of classification performance was then carried out in an
independent set of 9 myocardial infarction patients and 9 healthy
controls.
Results: Principal component 1 accurately classified an independent
collection of 9 MI’s and 9 healthy controls. The area under the
receiver-operating characteristic (ROC) curve for the classifier
developed from the PC1 analysis was 0.9.
Conclusions: Gene expression profiles isolated from CECs accurately
discriminate MI patients from healthy controls. This molecular sig-
nature may be useful for developing an assay for identifying
atherosclerotic plaque rupture preceding myocardial infarction.
Session: Revascularisation
42. Association of Non-Infarct Related Artery Coronary
Chronic Total Occlusion with Mortality in Patients
Presenting with ST-Elevation Myocardial Infarction:
A Systematic Review
and Meta-Analysis
O’Connor SA, Sanguineti F, Garcia AC, Hovasse T,
Unterseeh T, Morice MC, Benamer H, Lefe`vre T, Garot P, Louvard Y
Institut Cardiovasculaire Paris Sud: Institut Hospitalier Jacques
Cartier Massy, France
Purpose: To evaluate the impact of the presence of a chronic total
occlusion (CTO) on short and long term mortality after primary
percutaneous coronary intervention (PPCI).
Methods: We performed MEDLINE, Cochrane Controlled Trials
Registry and EMBASE database searches for published articles using
predefined terms. Studies that reported data on the incidence of all-
cause mortality in STEMI patients with single- or multivessel disease
(SVD, MVD) with and without CTO were included. Of the 189 studies
identified, 5 articles met the inclusion criteria: 3 observational studies
and 2 post hoc analyses of randomized controlled trials (RCTs).
Results: A total of 10,314 patients were included in the meta-analysis
with 4350 patients from observational analyses of RCTs, 5964 patients
in observational studies with overall 1160 (11 %) patients with CTO.
The global analysis demonstrated that CTO was associated with an
over threefold increased incidence of mortality at a median follow up
of 36 months compared to patients non-CTO patients (30.4 % vs
10.1 % OR: 3.24; 95 % confidence interval [CI]: 2.79 to 3.75;
p 0.0001) (Figure 1). This finding was consistent in a sub-analysis of
studies that reported 30-day follows up (17.6 vs 4.2 % OR: 4.3; 95 %
CI: 3.4 to 5.4 p = 0.001). Cardiac mortality and MACE were also
higher in patients with CTO (14.7 vs 3.7 % OR: 4.42; 95 % confidence
interval [CI]: 3.18–6.15; p \ 0.0001 and 33.5 % vs 20.4 % OR: 1.97;
95 % confidence interval [CI]: 1.56–2.47; p \ 0.0001 respectively).
Conclusions: Coronary chronic total occlusion in the non culprit
artery in patients presenting with STEMI is associated with poor long-
term mortality. Prospective randomized studies that examine the
impact on clinical outcome of revascularization strategies in this
population are indicated.
43. Appropriateness of Helicopter Transfer for Primary
Percutaneous Intervention in a National Acute
Coronary Syndrome Programme.
Colleran R, McInerney A, Mulveen V, Daly K
University College Hospital, Galway, Ireland
Introduction: The National ACS Programme advocates transfer of
STEMI patients from the field, or from outside hospitals (OSH)
directly to the catheterisation lab of primary PCI centres, bypassing
the ED, if feasible within 90 min of diagnosis, with target diagnosis to
reperfusion time less than 120 min, and an acceptable rate of inap-
propriate cath lab activation of 15 %. We are currently experiencing a
surge in helicopter transfer of such patients.
Aims: The aim of this study was to determine the appropriateness of
helicopter transfer of STEMI patients for pPCI, in terms of success
rates in prehospital diagnosis and in achieving target times.
Methods: Paramedic documentation and electrocardiograms of all
patients transferred directly to the catheterisation lab for pPCI by
helicopter over a 7 month period were reviewed.
Results: There were 51 helicopter transfers to the cath lab, 39
(76.5 %) from the field, 12 (23.5 %) from OSHs. 31 (79.5 %) field
STEMI diagnoses were correct. Of these, 30 had pPCI. 17 (56.7 %)
landed within 90 min of diagnosis (mean 91, SD 31.7 min), 12
(40 %) reached the lab within 90 min (mean 111, SD 31.8 min). 13
(43 %) were reperfused within 120 min (mean 135, SD 36.8 min).
There were 5 helicopter transfers from OSHs for pPCI. 1 (20 %)
achieved target arrival and reperfusion times. Mean diagnosis to
landing, cath lab admission and reperfusion times were 135 (SD
51.8), 149 (SD 65.9) and 174 (SD 66.0) minutes respectively. For the
remaining 4 cases (80 %), helicopter transfer delayed reperfusion
therapy as no patient had a contraindication to thrombolysis at OSH.
Conclusion: Among field transfers, prehospital diagnosis rate was
suboptimal but acceptable at this early stage of the programme.
Overall rates in achieving target times were also suboptimal, with
helicopter transfer sometimes causing unnecessary treatment delays.
Helicopter transfer for pPCI should utilised only if anticipated ECG to
Fig. 1
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pPCI centre door time is less than 90 min. Otherwise, immediate
thrombolysis should be considered prior to transfer.
44. Continuous Quality Improvement in the National
ACS Programme, The West of Ireland Experience
to Date.
Colleran R, McInerney A, Mulveen V, Walsh R, Sharif F,
Nash P, MacNeill B, Crowley J, Daly K
University College Hospital, Galway, Ireland
Introduction: The national ACS programme was implemented in
2012 to improve and standardise care of STEMI patients. Goals
include (i) primary PCI in 80 % of STEMIs, (ii) increased prehospital
diagnosis, (iii) diagnosis to door time \90 min and reperfusion time
\120 min, (iv) bypassing non-PCI centres if expected times within
target, (v) immediate transfer of thrombolysed patients to designated
PCI-centre with early angiography, (vi) early repatriation to non-PCI
hospitals, and (vii) length of stay (LOS) \4 days.
Aim: The aim of this study was to measure performance at our
institution against these key performance indicators (KPIs).
Methods: Performance in the first 6 months of the programme was
compared with that in the preceding 6 months.
Results:
Primary PCI
97 STEMI patients were admitted to our institution in the first
6 months of the programme versus 77 in the preceding 6 months. 78
(80.4 %) versus 49 (60.63 %) patients had pPCI respectively,
(p = 0.01). 37 (38.1 %) versus 10 (12.9 %) were diagnosed prehos-
pital with direct cath lab transfer, (p = 0.001). 20 (20.6 %) versus 1
(1.3 %) bypassed a non-PCI hospital, (p = 0.002). ECG to door time
was \90 min in 67.7 % versus 74.1 %, (p = 0.05). ECG to RT was
\120 min in 53.6 % versus 64.3 %, (p = 0.27).
Thrombolysis
12 (12.4 %) versus 15 (19.5 %) had thrombolysis (p = 0.84), with
immediate PCI-centre transfer in 11 (91.6 %) versus 13 (86.6 %),
(p = 0.55). 4 (33.3 %) and 7 (46.6 %) required rescue PCI respec-
tively. Of the remainder, 5 of 7 (71.4 %) versus 3 of 6 (50 %) had an
angiogram within 24 h of thrombolysis, (p = 0.21).
Repatriation/LOS
30.9 % versus 14.3 % were repatriated to a non-PCI hospital,
(p = 0.01). 55.8 % versus 58.6 % had a LOS of 4 days or less,
(p = 0.15).
Conclusion: Implementation of the ACS programme significantly
improved performance in all areas but target times and LOS. More
emphasis needs to be placed on these areas with serial assessment of
KPIs to ensure continuous quality improvement.
45. Retrograde Autologous Prime: Is There
an Association Between Improved Haemoglobin
Content During Adult
Cardiac Surgery?
Haughey N, Booth K, Jeganathan R
Dept of cardiac Surgery, Royal Victoria Hospital, Belfast, NI
Introduction: As a major blood consumer speciality, the risk of
blood transfusion in cardiac surgery are studied and known. An
Article by Murphy et al., showed no benefit from transfusion for
haemoglobins as low as 70 g/l and the risk of death within 30 days, 6
times higher in those who were transfused following cardiac surgery.
RAP (Retrograde Autologous Prime) is a method of priming both the
arterial and venous line with the patient’s own blood to reduce hae-
modilution and reduce the likelihood of transfusion both intra and
post operatively.
Methods: From July 2012 to October 2012, patients were prospec-
tively studied following either Retrograde Autologous Priming (RAP)
(study group) versus Non Retrograde Autologous Priming (NonRAP)
(control group). All data was prospectively collected and included
age, sex, logistic euroscore, procedure, co-morbidities, haemoglobin
and hematocrit pre-op, on pump and post op day 0,1,2 and 5. All
patients were followed up until discharge.
Results: A total of 46 patients were looked at over the 3 month
period. The demographics of the two groups are highlighted in
table 1. Transfusion rates were observed in the two groups of patients.
In the study group 30.4 % of patients received blood transfusion and
in the control group the rate was 60.9 %.
Table 1. Study Demographics
Study Group (RAP) Control Group (NonRAP)












8 (2) 5 (0)
Percentage elective 65 % 70 %
CPB time (mean) 123 (range 44–385) 135 (range 70–239)
Cross-clamp time
(mean)
86 (range 26–290) 102 (range 42–194)
Percentage of
CABG only
60.7 % 47.8 %
Conclusion: This audit highlight’s RAP as an important method in
blood conservation following cardiac surgery.
46. Optical Coherence Tomography in the Days
Following Primary PCI; Sobering Findings
Ryan N, Foley DP
Beaumont Hospital, Dublin, Ireland
Background: Primary coronary intervention (PPCI) is the gold
standard for reperfusion in ST elevation myocardial infarction
(STEMI). A National PPCI strategy has recently been rolled out
nationwide with direct ambulance transfer of STEMI patients to PPCI
centres. Optimal stent result is key to achieving best outcomes with
PPCI, however patients with STEMIs are a challenging and high-risk
heterogenous group. The Dutch Stent Thrombosis Registry has
identified undersizing of stents, uncovered dissections and disease
distal and proximal to the stent as major predictors of stent throm-
bosis. These features are all remediable by optimal stenting but not
easily detectable by angiography. Optical Coherence Tomography
may be useful in identifying these features however it is not univer-
sally available in PPCI centres.
Ir J Med Sci (2013) 182 (Suppl 8):S359–S392 S385
123
Aim: Review the findings and implications of OCT during early
relook coronary angiography post PPCI.
Methods: The Cardiac Intervention Suite register for the period
January 2012 to March 2013 was reviewed along with electronic
procedure records.
Results: Between January 2012 to March 2013, 80 patients had OCT
of whom 13 had a recent PPCI. The average age of the patients was
56.9 years, 7 were male. One did not have stenting during PPCI.
The culprit artery was the LAD in 46.1 % and RCA in 38.4 %.
OCT of the culprit artery showed significant stent undersizing and
malapposition requiring optimization in 84 % of cases, with sig-
nificant distal disease in 53.8 % and significant proximal disease in
23 %. In one case a large edge dissection of the stent was identi-
fied. Varying degrees of organized thrombus were identified in most
cases.
Conclusion: Culprit artery OCT carried out 2–4 days post successful
PPCI in a consecutive unselected patient series revealed stent un-
dersizing, malapposition and additional significant unstented coronary
disease in the majority of patients. These findings raise concerns
regarding methods of stent sizing and postdilatation during PPCI and
suggest we are consistently too conservative. OCT should be avail-
able in all PPCI centres and should be considered during PPCI or
electively in the succeeding days.
47. Pre-Hospital Diagnosis of STEMI: Is Electronic
Electrocardiogram Transmission Superior
to Paramedic Catheterisation Lab Activation
Colleran R, McInerney A, Daly K
University College Hospital, Galway, Ireland
Introduction: Prehospital STEMI diagnosis with direct cardiac
catheterisation lab transfer, with an emergency department bypass
strategy, significantly reduces door to balloon (DTB) time in primary
percutaneous intervention (pPCI). Prehospital diagnosis may be made
by paramedics in the field or by a physician via electronic ECG
transmission to a hospital-based computer or smart phone. At present,
despite a national acute coronary syndrome programme, electronic
ECG transmission is possible in only some ambulances in the west of
Ireland, and national implementation of such a system would be costly.
Aims: The aims of this study were to investigate whether electronic
ECG transmission, reduced the rate of inappropriate cardiac cathe-
terisation lab activation in the west of Ireland, and to determine
whether prior ECG transmission improved DTB time in these
patients.
Methods: All patients transferred by ambulance directly to the cath
lab as a ‘Code STEMI’ over a fifteen month period were included.
Transmitted ECGs on the LIFENET system were matched with
corresponding patients.
Results: In total, 76 patients were transferred directly from ambu-
lance to cath lab with a prehospital diagnosis of STEMI. 46 (60.5 %)
had prior ECGs transmission. Of these, there were 6 (13.0 %) inap-
propriate referrals versus 7 (23.3 %) in the 30 patients without ECG
transmission (p = 0.09). The mean door to balloon time for those
with transmitted ECGs was 42.9 min versus 41.0 for those without
(p = 0.76).
Conclusion: ECG transmission did not significantly reduce the rate of
inappropriate cath lab activation. Moreover, ECG transmission did
not impact on DTB time in patients transferred directly to the cath lab.
ECG transmission did not confer any significant advantage in this
small patient cohort. This should be reassessed in time with a larger
sample size.
48. ATOLL Bio-Thrombotic Markers 1
O’Connor SA, Ankri A, Kerneis M, Abtan J, Brugier D, Galier S,
Silvain J, Vicaut E, Collet JP, Montalescot G
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re
Hospital (AP-HP), Universite´ Paris, France
Background: The ATOLL (Acute ST-elevation myocardial infarc-
tion Treated with primary angioplasty and intravenous enoxaparin Or
unfractionated heparin to Lower ischemic and bleeding events at
short- and Long-term follow-up) randomized trial showed that
intravenous heparin compared with unfractionated heparin (UFH)
significantly reduced ischemic events.
Purpose: The study aimed to assess biomarkers of coagulation and
platelet activation in patients on intravenous enoxaparin or UFH in
the primary PCI (PPCI) setting with significant antiplatelet therapy
and to correlate these findings with 1 month clinical outcomes.
Methods: Patients presenting with STEMI that were randomized to
receive an intravenous bolus or either enoxaparin or UFH had blood
sampling performed at sheath insertion at the commencement (T1)
and at the end of the PPCI procedure (T2). The thrombotic factors,
von Willebrand factor antigen (vWFAg), prothrombin fragment 1 + 2
(F1 + 2), thrombin-antithrombin (TAT) complex, tissue factor path-
way inhibitor (TFPI) were measured along with the platelet marker,
soluble CD40 ligand (sCD40L).
Results: A total of 129 patients (n = 58 enoxaparin and n = 71
UFH) were included. Of the numerous parameters measured, uni-
variate analysis identified significant association between increased
plasma levels of F1 + 2 and TAT measured at T2 and the incidence of
the primary endpoint (p = 0.05 and p = 0.03) and the secondary
ischemic endpoint (p = 0.035 and 0.036). The increasing release of
F1 + 2 between T1 and T2 (D T2-T1) also predicted the primary
(184.9 ± 61.1 vs 3.2 ± 34.7 pmol/L, p = 0.01) and secondary end-
points (318.8 ± 132.2 vs 36.9 ± 30.3 pmol/L, p = 0.05).
Multivariate analysis identified increased plasma levels of F1 + 2 and
TAT complex as independent correlates of the secondary ischemic
endpoint at 1 month.
Conclusions: In this substudy of the ATOLL trial, markers of
thrombin generation F1 + 2 and TAT complex are independently
associated with short-term adverse ischemic events in PPCI patients.
49. ATOLL Thrombotic Markers 2
O’Connor SA, Kerneis M, Ankri A, Abtan J, Brugier D, Silvain J,
Ecollan P, Vicaut E, Collet JP, Montalescot G
Institut de Cardiologie, INSERM UMRS937, Pitie´-Salpeˆtrie`re
Hospital (AP-HP), Universite´ Paris, France
Background: The ATOLL (Acute ST-elevation myocardial infarc-
tion Treated with primary angioplasty and intravenous enoxaparin Or
unfractionated heparin to Lower ischemic and bleeding events at
short- and Long-term follow-up) randomised trial showed that intra-
venous enoxaparin compared with unfractionated heparin (UFH)
significantly reduced ischemic events with non significant reductions
in bleeding complications.
Purpose: To compare the efficacy of enoxaparin and UFH in
achieving target anticoagulation levels during percutaneous coronary
intervention.
Methods: This was a single centre biological sub-study. Patients
presenting with STEMI that were randomized to receive an intrave-
nous bolus or either enoxaparin or UFH had blood sampling
performed at sheath insertion at the commencement (T1) and at the
end of the PPCI procedure (T2). To demonstrate pharmacological
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efficacy we chose target ranges of 0.5–1.2 IU/ml for anti Xa levels for
enoxaparin and 1.5–2.5 IU/ml activated partial thromboplastin time
(APTT) ratio for UFH treated patients.
Results: A total of 133 patients (n = 58 enoxaparin and n = 71
UFH) were included. Of these 51 patients (n = 20 enoxaparin,
n = 31 UFH, p = 0.288) were randomized pre-hospital in the mobile
intensive care unit (MICU). In the pre-hospital treatment group more
patients treated with enoxaparin were on-target than UFH at both T1
(78.9 vs 15.4 %), p \ 0.0001) and T2 (84.2 vs 32.1 %, p = 0.0008).
These findings were consistent in the overall group regardless of
upstream treatment with target anticoagulation levels at T2 more
readily achieved in patients receiving enoxaparin (80 % vs 18.2 %,
p \ 0.0001). Anti Xa and APTT ratio levels did not correlate with
major or minor bleeding (p = 0.83, 0.72). Likewise there was no
correlation between anticoagulation levels and ischemic events
(p = 0.76).
Conclusions: In STEMI patients undergoing primary PCI target
anticoagulation levels were more readily achieved in patients
receiving intravenous enoxaparin than UFH. The more predictable
and stable anticoagulation obtained with enoxaparin may explain the
better outcomes observed in the main study.
50. Management of Allograft Vasculopathy Post
Cardiac Transplant in the Era of Drug Eluting Stents
Canniffe C, Neylon A, Parlon B, Egan J, McCarthy J, Mahon NG,
O’Neill JO
Mater Misericordiae Hospital, Dublin, Ireland
Purpose: Cardiac allograft vasculopathy (CAV) post transplant
remains a problematic issue with no consensus on optimal man-
agement. We report on the long term outcomes of a cohort of
patients with CAV treated with percutaneous coronary intervention
(PCI).
Methods: We reviewed the medical records of all patients who
underwent PCI with drug eluting stents (DES) for the management of
CAV in a national transplant centre between 2002–2007.
Results: 15 patients underwent revascularisation therapy with DES.
93 % male. The mean time from cardiac transplant to intervention for
CAV was 10.7 years (±3.5 years).
Mean (±SD)
Age at Transplant(years) 45.6
(±12.36)
Male (%) 93
History of Tobacco Use (%) 40
Hypertension (%) 40
Drug treated dyslipidaemia (%) 66.6
Diabetes Mellitus (%) 0
Successful stent deployment (defined as \50 % residual stenos-
es) occurred in 100 %. The left anterior descending artery was the
commonest target vessel (66.6 %) for intervention. Stents used were
predominantly Paclitaxel (33.3 %) and Sirolimus (46.6 %). The
mean diameter and length of stents deployed was 3.57 mm
(± 2.3 mm) and 23.8 mm (± 12.5 mm) respectively. 1 patients died
during revascularisation therapy. Overall 30 day mortality was
13.3 %.
33.3 % (5 patients) patients were alive and free from re-transplanta-
tion at a mean follow up of 8.14 years (±2.08 years).
40 % of patients demonstrated C moderate instent restenosis at fol-
low up angiography at a mean of 35.6 months (±13.17 months) post
initial revascularisation therapy.
Conclusion: Patients who undergo coronary revascularisation with
DES for allograft vasculopathy continue to have a high mortality rate
despite intervention.
51. Application of ESC Guidelines to Rationalise
Acceptance Criteria and Streamline Inpatient Cardiac
Catheterisation
Tweedie J, Niall Herity N
Belfast City Hospital, Belfast, NI
Background: Over 2,000 patients are referred to the Belfast Trust
annually for inpatient cardiac catheterisation. Individual consultant
review and decision-making leads to avoidable scheduling delays and
friction when a referral is declined.
Aim: The aim of this project was to produce a regionally-agreed
matrix based on ESC guidelines for inpatient cardiac catheterisation
and to evaluate it against a real-world cohort of referrals.
Methods: Using six sets of European society of cardiology (ESC)
guidelines, acceptance criteria were identified, summarised and
agreed across the region. Forty consecutive electronic referrals were
the selected, anonymised and circulated to a wide range of cardiol-
ogists from both referring and receiving hospitals. They were asked to
grade whether the referral should be accepted or declined and the
expected timescale for completion of accepted procedures.
Results: The agreed matrix identified most acute coronary syndromes
and ventricular arrhythmias as suitable for inpatient catheterisation
and most valvular disease, most heart failure and stable angina as not
suitable. Most referrals were for acute coronary syndromes (35/40;
NSTEMI 29/40, STEMI 6/40) with smaller numbers referred for
ventricular arrhythmias (2) valvular disease (2) and stable angina
(1)Cardiologists graded referrals in line with agreed criteria, but with
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residual clinical variation (Table). For acute coronary syndromes the
majority of respondents believed that cases could be reliably assessed
and graded by a nurse scheduler; for all other clinical categories this








Stable angina (1) No 3/13 10/13
Valvular heart disease (2) No 4/24 20/24










Conclusions: An ESC guideline-based decision matrix has the ability
to harmonise referral and acceptance criteria for inpatient cardiac
catheterisation. This has greater applicability to patients with acute
coronary syndromes (the majority) than to other clinical situations.
52. In The Current Era of ST Elevation Myocardial
Infarction Treatment, Which Patients are Not
Reperfused? An Observational Analysis
1McGovern L, 2Kiernan T
1University College Cork, Ireland, 2University Hospital Limerick,
Limerick, Ireland
Background: The current treatment of ST elevation myocardial
infarction (STEMI) is mechanical reperfusion by Primary Percuta-
neous Coronary Intervention (PPCI) or systemic thrombolysis.
Several factors are related to non-reperfusion, with advanced age
being particularly significant. At present, no study has examined the
presentation and characteristics of the non-reperfused patient in Ire-
land. Further study is clearly needed in this area, especially as the
older demographic of the population increases.
Aim: To define, understand and critically evaluate STEMI patients
who do not receive reperfusion therapy.
Methods: The Coronary Heart Attack Ireland Register (CHAIR) was
used to identify STEMI patients who did not receive reperfusion
therapy between January 1st 2007 and December 31st 2011. A ret-
rospective review of patient charts was performed at Cork University
Hospital, Mercy University Hospital, South Infirmary Victoria Uni-
versity Hospital and Mallow General Hospital. The contribution of
non-reperfusion to patient mortality was also examined in terms of
30-day mortality and 1-year mortality post STEMI.
Results: 77 cases were included. Results indicate that most were female
(N = 47, 61 %) with a median age of 80.39 years. 54.5 % (N = 42)
had a past medical history of coronary heart disease with hypertension
being the main risk factor (N = 43, 55.8 %). 49 % (N = 38) were
considered independent in terms of ADLs. Patient mortality at 30 days
post STEMI was 55.8 %. This increased to 61 % at 1 year.
Conclusion: As the older demographic in our population increases,
this patient cohort will become particularly significant. Mortality
among these patients is high yet a significant number were considered
independent in terms of ADLs. Prospective evaluation of this patient
cohort needs to take place to monitor the effect of the introduction of
the PPCI National Strategy in Ireland in 2012. Internationally, larger
studies are needed to determine the role of social factors as predictors
of non-reperfusion.
53. Audit of Rates and Timeframe of Radial Artery
Occlusion Post Radial Angiography
O’Neill L, Chandra R, Fahy C, Mc Carthy-Deering E, Cronin E,
Owens P
Waterford Regional Hospital, Waterford, Ireland
Introduction: Rates of radial artery occlusion (RAO) post angiog-
raphy vary between 1 and 20 %. It is generally asymptomatic
however impacts on method of access for future angiography.
Aims: Audit the rate of RAO in patients undergoing coronary angi-
ography in a single centre and identify timeframes with regard to both
occlusion and recanalization.
Methods: Patients undergoing elective outpatient coronary angiogra-
phy ± PCI were prospectively enrolled. All had radial artery patency
confirmed pre procedure using the Allen’s test. Patientsunderwent a reverse
Allen’s test at 1 day, 1 week and 1 month post procedure. Ultrasound of the
radial artery was carried out in the case of an abnormal result.
Results: Thirty patients have been enrolled to date seven of which are
female. Twenty-four procedures were diagnostic and six interven-
tional. All patients had a 6Fr radial sheath inserted. Diagnostic
catheters were 5 Fr and guides were 6 Fr. All patients received 3000
units of heparin plus top up heparin according to weight in interven-
tional cases. In addition 46 % of patients received intra- arterial
verapamil as per operator preference. The mean duration of the pro-
cedure was 31.3 min. RAO was confirmed by ultrasound in three
patients. All of these had abnormal clinical exam at 24 h post proce-
dure. Two had undergone diagnostic procedures of 20 min duration
and had received 3000 units of heparin. One had undergone an FFR
assessment of 40 min duration and had received standard and top up
heparin plus verapamil. This patient had had a previous interventional
procedure 2 weeks prior. There was no clinical evidence of recanali-
zation at one month post RAO confirmation in all three.
Conclusion: Provisional results suggest that RAO occurs early post
angiography and that recanalization takes at least a month. Prior recent
angiography may be additional risk factor for development of RAO.
54. A Real World Comparison of Outcomes
in Transradial Versus Transfemoral Access
for Primary Pci: Single Centre Experience
Colleran R, Durcan R, Judge C, Nolan P, Sharif F
University College Hospital, Galway, Ireland
Introduction: The ESC recommends transradial (TRA) over trans-
femoral access (TFA) as the default access route for primary PCI
(pPCI). The aim of this study was to explore whether real world
outcomes with TRA were superior in a centre where all operators are
proficient in both transradial and transfemoral PCI.
Methods: This was a retrospective observational analysis. All
patients who had pPCI over a 1 year period were divided into 2 arms,
depending on access route. Patients with access site crossover and
those in cardiogenic shock were excluded. Baseline patient and pro-
cedural characteristics and outcomes were recorded.
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Results: There was no difference in baseline characteristics, other
than use of significantly more antithrombotic therapy in the TRA arm
(table 1). Despite this, TRA was associated with lower contrast vol-
umes, shorter CCU LOS, fewer access site complications, and less
bleeding (table 2). The latter two were driven by a reduction in TIMI
minor and minimal bleeding.
Conclusions: Consistent with recent trials, TRA was associated with
better outcomes than TFA. We failed to demonstrate a reduction in
major bleeding or mortality, however, in this small study.
55. A Study in Syncope: A Review of 94 Tilt Table Tests
Monaghan M, McCarron M, Purvis J.
Departments of Cardiology and Neurology, Altnagelvin Hospital,
Western HSC Trust, Londonderry, NI
Recurrent syncope (RS) and postural tachycardia (POTS) can be
difficult to diagnose and treat effectively. A tilt table test (TTT)
provides orthostatic stress whilst heart rate (HR) and blood pressure
(BP) are measured. We reviewed 94TTTs performed over 6 years to
assess the usefulness of this investigation.
Altogether, 27 males (29 %, average age = 36) and 67 females
(71 %, average age = 33) underwent TTT. Under-18 s comprised
20 % of the population. 12 % of studies were requested by Neurology.
SYNCOPE: 59 tests were performed (average age = 39,
71 %female). 29 tests (48 %) were positive plus 2 patients had epileptic
seizures. Of those with positive TTTs; 19 (68 %)commenced Midodrine,
4 (14 %) received advice, 3 (11 %)commenced Fludrocortisone, 1 (3 %)
commenced scopolamine patches and 2 (7 %) required pacemaker.
Amongst patients with negative tests; 2 were diagnosed with
POTS due to inappropriate HR rise, and 2 with fast HR throughout
were diagnosed as Inappropriate Sinus Tachycardia (IST).
POTS: 35 tests were performed (average age = 25, 74 %female).
18 tests (53 %) were positive and 1 patient was diagnosed with
postural cerebral hypoperfusion following onset of headache on TTT.
Of those with positive result; 8(44 %) received advice, 6(33 %)
commenced Midodrine, 2(11 %) received Fludrocortisone, 1 com-
menced Bisoprolol (for postural palpitations) and 1 commenced
Clonidine (for hyperadrenergic POTS—raised BP on standing).Two
patients with negative tests were diagnosed with IST due to elevated
flat HR response.
Conclusion: TTT can serve as a useful guide to diagnosis and
treatment in both recurrent syncope and POTS.
56. Electrocardiographic Criteria for Predicting Infarct
Related Artery Occlusion in Inferior Wall Acute
Myocardial Infarction
Elhanan M, Hamra M, Ali M, Murray D
Sligo Regional Hospital, Sligo, Ireland
Background: Classically two arteries are usually involved in trig-
gering inferior ST elevation MI, the right coronary artery (RCA) and
the left circumflex artery (LCX). Its frequently possible to estimate the
site of the infarct from the ECG and therefore estimate the culprit
artery, this information is clinically significant as it provide prognostic
mark as well as predicting the possible adverse outcomes.
Study Objectives: Primary objective is identification of the culprit
coronary artery involved in the setting of acute inferior STEMI
whether found to be RCA or LCX by assessing the 12 leads surface
ECG in patients with acute inferior wall STEMI.
Secondary objective is to predict any possible correlation between the
proximity of the lesion in the RCA and the degree of ST elevation in
the inferior ECG leads in inferior ST elevation myocardial infarction
related to RCA occlusion.
Study Design: Retrospective review.
Methods: 45 consecutive patients diagnosed with acute ISTEMI in
Sligo Regional Hospital between 2010 and 2012 were included,
standard 12 leads surface ECG recorded within 24 h of onset of
symptoms, and all had Coronary within 7 days of presentation. ST
segment elevation or depression was measured 0.08 s after the J point.
Patients with LBBB on ECG, previous myocardial infarction, sig-
nificant multi vessel disease, paced rhythm, or significant artefact on
ECG were excluded from the study.
Conclusion: We were able to predict the IRA in case of ISTEMI
through analysis of ST segment deviation on certain leads. The cri-
terion of ST elevation III [ II +ST segment depression lead
aVL C 0.5 mm predicts the RCA as infarct related artery with
specificity of 92 % and PPV of 94 %. LCX artery can be as well
predicted as IRA with specificity of 96 % and PPV of 88 % when the
criterion of ST elevation lead II [ III + ST segment depression leads
V1 and or V2 is used.
We also found the proximity of the RCA lesion in the RCA group is
directly proportionate to the mean of the summated total ST segments
elevation in leads II, III, aVF, the difference is remarkable and highly
significant specially when comparing between the means for the






Age 60.9 (SD 12.3) 63.5 (SD 12.9) 0.27
Male 48 (77.4 %) 41 (74.5 %) 0.71
Heparin dose (SD) 7306 (1493) 6184 (1337) 0.001
GPIIbIIIa inhibitor 30 (48.4 %) 17 (30.9 %) 0.05
Thrombus aspiration
catheter
44 (70.9 %) 41 (74.5 %) 0.67
Number of lesions stented 1.15 (0.44) 1.13 (0.34) 0.81
Number of stents deployed 1.61 (0.89) 1.9 (1.0) 0.14
6 French sheath 62 (100 %) 55 (100 %)
Staged inpatient PCI 8 (12.9 %) 7 (12.7 %) 0.49
Table 2
Outcomes Radial Femoral p-value
Procedure time 29.0 (SD 12.0) 26.6 (SD 11.5) 0.32
Fluoroscopy time 12.1 (6.4) 13.7 (7.9) 0.24
Radiation dose (mGycm2) 13075 (10838) 14071 (9685) 0.61
Contrast volume (ml) 225 (65) 251 (75) 0.04
Time to ambulation (days) 1.3 (1.1) 1.5 (0.92) 0.3
CCU LOS 3.1 (2.3) 3.8 (1.9) 0.049
Overall LOS 4.4 (1.81) 4.8 (1.72) 0.22
Access site complication 0 5 (9 %) 0.01
Bleeding 0 6 (10.9 %) 0.01
TIMI major bleeding 0 2 (3.6 %) 0.13
Inpatient mortality 2 (3.2 %) 2 (3.6 %) 0.96
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57. Early Experience of Cardiac Exercise Testing
in A Primary Health Care Facility
1O Casaide S, 1Cuddihy B, 2King G, 2Kindler H, 2Clarke J,
1Ayrfield Medical Centre Kilkenny, Ireland, 2Eagle Lodge (Aut Even
Hospital Kilkenny), Ireland
Aim: Exercise stress testing (EST) is a screening tool for coronary
artery disease (CAD). Previous studies show an overall sensitivity of
67 % and specificity of 72 % with variable predictive values. The
purpose of the current study was to evaluate the predictive value of
EST in a new Primary care facility in Kilkenny.
Methods: This is a retrospective case series of 223 ESTs performed in a
primary care facility from July 2012 to April 2013. EST results were
classified as positive, negative, or equivocal. Outcomes studied from a
review of outpatient and inpatient electronic medical record data inclu-
ded myocardial infarction, cardiac catheterization with angioplasty and
stenting, coronary artery bypass grafting, a new diagnosis of CAD.
Results: Nearly all patients had low to intermediate risk pretest
probability. 18 were positive, 35 were equivocal, and 170 were
negative. There were 5 false-positive tests. There were 5 false-neg-
ative tests, 4 of which were treated with good outcomes. Out of the 35
equivocal results 5 had cardiac outcomes. Considering equivocal tests
as positive, the overall sensitivity in this series was 72 %; specificity
was 96 %. The positive predictive value was 18 % and the negative
predictive value was 97 %.
Conclusions: The high negative predictive value for EST in this
outpatient GP practice population is significant and reassuring. EST is
a cost-effective strategy for triaging chest pain in low- to intermedi-
ate-risk patients in primary care facilities and should be included in
the services offered to Primary care facilities which can reduce the
burden on overstretched hospital resources.
58. Night Time Blood Pressure And Sub-Clinical Target
Organ Damage: Findings from an Irish Primary Care
Based Population Sample
O’Flynn AM, Kearney P, Curtin R, Perry I
University College Cork/Cork University Hospital, Cork, Ireland
Introduction: The prognostic significance of nocturnal blood pressure
is well recognised. The dipping phenomenon was first described by
O’Brien and colleagues in 1988. More recently the focus has been on
absolute levels to classify night-time blood pressure. Our aim is to
determine whether dipping status or absolute night-time blood pressure
levels are better associated with subclinical target organ damage.
Methods: The Mitchelstown Cohort was established to examine
cardiovascular health in a middle-aged Irish adult population based
sample recruited from one large primary care centre. Of 2047 par-
ticipants 1207 (response rate 59 %), under-went 24 h ambulatory
blood pressure monitoring. We excluded 135 studies due to incom-
plete data. Night-time blood pressure was classified by absolute levels
and dipping status. Subclinical target organ damage was defined by
Cornell Product ECG left ventricular hypertrophy (LVH) voltage
criteria and urine albumin:creatinine ratio (ACR) [1.1 mg/mmol.
Multi-variable logistic regression analysis was used to assess the
association between night-time blood pressure and target organ
damage.
Results: Of 1072 patients, 255 (24 %) had day-night hypertension
and 64 (6 %) had isolated nocturnal hypertension [94 % of these were
non-dippers or reverse dippers]. 165 (28 %) of the dippers had ele-
vated night-time blood pressure. In the multivariable analysis each
10 mmHg rise in night-time systolic blood pressure resulted in an
approximate doubling of risk for target organ damage. Odds ratio
(OR) for ACR = 1.84(95 % CI 1.05–3.23) and OR for
LVH = 2.20(95 % CI 1.13–4.27).
Discussion: Nocturnal hypertension rather than dipping status may be
a better way to classify night-time blood pressure. Further interven-
tional studies are required to determine if there is a benefit in reducing
absolute night-time blood pressure levels.
59. Retrospective Analysis on Lipid Profiles in Very
High Risk Patients Requiring PCI. Are We Adhering
to the Guidelines?
Lim RY, Fitzpatrick N, Barry T, Ahern C, Abdalla A, Hussainni A,
Lobo R, Stack A, Kiernan T.J, Hennessy T, Meany B, Abbass S, Hynes
B
University Hospital Limerick, Limerick, Ireland
Introduction: European Society of Cardiology (ESC) guidelines
recommends Low Density Lipoprotein (LDL) levels with a class 1
recommendation for target LDL of \1.8 mmol/L in patients with
established coronary artery disease. We studied a cohort of patients
presenting to University Hospital Limerick (UHL), Ireland, aiming to
establish if there was significant improvement in patient lipid profile
after PCI and whether adherence to ESC guidelines for secondary
prevention was achieved in real life.
Methods: 243 patients presented to UHL for PCI from Jan 2012 –
April 2013. Lipid profiles obtained at baseline (lipid profile during
same admission for PCI and at follow up at post PCI clinic were
analysed. A sub-study was carried out to establish for adherence to
ESC guidelines where patient LDL levels were divided into three
groups:\1.80, 1.81–2.5 and[2.5 mmol/L to establish the percentage
of patients in each category.
Results: The mean time from baseline to follow up was 41.5 (SD










TC 4.57 (SD 1.13) 3.72 (0.91) \0.001
LDL 2.69 (SD 0.96) 1.89 (0.71) \0.001
HDL 1.13 (SD 0.36) 1.21 (0.37) \0.001
Triglyceride 1.59 (SD 1.07) 1.32 (0.81) \0.001
Analysing for adherence to ESC guidelines, there was significant
improvement in patients adhering to ESC guidelines.
LDL level (mmol/L) At baseline At Follow up
\1.80 52 (21.4 %) 136 (56.0 %)
1.81–2.5 63 (26.0 %) 65 (26.7 %)
[2.5 128 (52.7 %) 42 (17.4 %)
Conclusion: Our study provided evidence of improvement in lipid
profiles after PCI. There was significant reduction in TC, LDL and
Triglyceride level and significant increase in HDL levels. However,
only 56.0 % of patients met ESC guidelines for LDL control post
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PCI. Even in the modern era of high dose statin post ACS, many
patients (46.6 %) were not meeting ESC recommendations.
Session: Heart Failure/General Cardiology
60. STEMI Care in Ireland: Initial Experience of a New
National Protocol and Information System
1Jennings S, 2Cavanagh B, 3 Daly K
1Dept of Public Health, HSE. 2HSE South. 3University College
Hospital Galway, Ireland
Background: The Acute Coronary Syndrome (ACS) Clinical pro-
gramme in the HSE initiated the national Optimal Reperfusion
Service (ORS) in October 2012 in the West and South of Ireland
followed by Dublin, North East and Midlands in January 2013 with
the purpose of standardising and improving care of ACS patients.
A new monitoring mechanism, Heartbeat Portal, was developed in
2011 based on previous national and international experience. The
purpose was to monitor key indicators of performance of the clinical
programme.
Methods: Based on a previous initiative and international guidance, key
performance indicators (KPIs) were established for monitoring. A data set
with definitions and a new electronic collection mechanism, based on
clinical data capture on HIPE, was agreed, piloted and initiated. Mecha-
nisms for completeness, validation and analysis have been put in place.
The initiative focussed on key components of STEMI patient care ini-
tially—reperfusion therapy type and timeliness, discharge medications,
smoking cessation counselling and referral for cardiac rehabilitation.
Results: Analysis of data for the first 3 months (Oct to Dec, 2012)
from four hospitals is described here. Data for 9 months will be
available by Sept, 2013.
138 patients with STEMI were recorded with a mean age of
63.5 years and 73.9 % male. The first positive ECG was largely taken
in Emergency Department (52.9 %) or Ambulance (38.4 %).
Excluding those contraindicated, 89 % of patients received Primary
PCI and 69 % received Primary PCI within 120 min of 1st diagnostic
ECG. Provisional outcomes show an in-hospital mortality of 6.5 %
and a stroke rate of 4.3 %.
Conclusion: We describe the first three months of the new national
optimal reperfusion service and a new information system. Using the
Heartbeat portal aligned as it is with HIPE, offers a sustainable system
of capture of demographic and clinical data for monitoring care of
STEMI patients.
61. Trends in Hospitalisation for Acute MI in Ireland
1997–2008
1Jennings SM, 2Bennett K, 2Lonergan M, 1Shelley E
1Department of Public Health, HSE, Dublin, 2 Department of
Pharmacology and Therapeutics, Trinity Centre for Health Sciences,
St James’s Hospital, Dublin, Ireland
Objective: To study temporal and gender trends in age standardised
hospitalisation rates, in-hospital mortality rates and indicators of
health service use for acute myocardial infarction (AMI) and the sub-
categories ST elevation MI (STEMI) and non-ST elevation MI
(NSTEMI) in Ireland, 1997–2008.
Design, Setting, Patients: Anonymised data from the Hospital In-
Patient Enquiry were studied for the ICD codes covering STEMI and
NSTEMI in all 39 acute hospitals in Ireland over a 12 year period. Age
standardisation (direct method) was used to study hospitalisation and
in-hospital mortality rates. Joinpoint regression analysis was under-
taken to identify significant inflection points in hospitalisation trends.
Main Outcome Measures: Age standardised hospitalisation rates, in-
hospital mortality and indicators of health service use (length of stay,
bed days) for AMI, STEMI and NSTEMI patients.
Results: From 1997 to 2008 hospitalisation rates for AMI decreased
by 27 % and by 68 % for STEMI patients (test for trend p \ 0.001),
and increased by 122 % for NSTEMI, (test for trend p \ 0.001).
The mean age of male STEMI patients decreased (p \ 0.01) while
those for the remaining groupings of AMI and subcategories
increased. The proportion of males increased significantly for
STEMI and NSTEMI (p \ 0.001). In-hospital mortality decreased
steadily (p = 0.01 STEMI, p = 0.02 NSTEMI), as did median
length of stay.
Conclusions: We find a steady decrease in hospitalisation rates with
AMI and a shift away from STEMI towards rising rates of NSTEMI
patients who are increasingly older. In an ageing population and
with increasing survival, surveillance of acute coronary syndrome
and allied conditions is necessary to inform clinicians and policy
makers.
62. A National Evaluation of the Aspirin Response
Kenny D
The National Cardiovascular and Stroke Research Network, RCSI,
Dublin, Ireland
Cardiovascular disease is the leading cause of death in most developed
countries. There is strong evidence for the net benefits of aspirin in
decreasing the risk of cardiovascular events in a wide range of patients.
Nevertheless a significant proportion of patients experience recurrent
cardiovascular events. With the advent of platelet function testing the
concept of aspirin resistance or non-response has emerged. There is no
clear data in Ireland on the therapeutic response to aspirin in patients
with coronary artery disease. To address this question, at a national
level, the first study of the National Cardiovascular and Stroke
Research Network (NCSRN) prospectively evaluated the response to
aspirin in 700 patients with stable coronary artery disease. Patients
aged 18 years or older with a documented history of coronary artery
disease on any dose of aspirin for 3 months were included in the study.
Patients with unstable coronary syndromes, known haematological
disorders or active malignancy were excluded. Demographic data were
recorded and a blood sample was taken for Thromboxane B2 (TxB2)
levels. All blood samples were analyzed in a central laboratory and
demographic data recorded in a central data base. An interim analysis
has shown that 20 % of the patients have a serum Tx of[2.2 ng/ml.
Using a cut point of 2.2 ng/ml this suggests that 20 % of patients in
Ireland with established coronary artery disease are not adequately
‘protected’ by aspirin. A preliminary analysis of the demographic data
has demonstrated that age, hypertension, weight and alcohol con-
sumption are risk factors for an inadequate response to aspirin. The full
results of this study on behalf of the NCSRN will, if accepted, be
presented at the Irish Cardiac Society in 2013.
63. Poor Cardiovascular Health of Patients Who Begin
Haemodialysis in the Mid West Region of Ireland:
A Pilot Initiative for a National Study
Roche D, Lim RY, Yermak D, Casserly L, Cronin C, Hannigan A,
Kiernan T, Stack A
Department of Nephrology, Department of Cardiology, University
Hospital Limerick, Ireland
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Background: Recent studies in the US have demonstrated increasing
acceptance of patients with a high burden of comorbid conditions and
earlier initiation of dialysis treatment. These trends have important
clinical, resource and economic implications. There is little data
available in Ireland. To improve our understanding in this area, we
analysed the characteristics of incident patients who were initiated on
long-term haemodialysis in the Midwest Region.
Methods: We compared the characteristics of all new haemodialysis
patients from 2009–2012 (n = 106). Data were extracted from clin-
ical records, discharge summaries, laboratory information system and
dialysis records using a standardised data collection instrument.
Comparisons were made with respect to demographic characteristics,
clinical conditions, laboratory measures, medication use, and process
indicators during the pre-dialysis period across calendar years.
Descriptive statistics and comparisons across years were conducted
using the wald Chi square and analysis of variance.
Results: The prevalence of cardiovascular conditions were high at
dialysis onset and were in general of the same magnitude/or greater
that US incident dialysis cohorts). The prevalence of coronary disease
was 39 %, Heart Failure 29 %, Stroke 16.3 % and the average serum
albumin level was 28.3 (±5.5) g/L. Measurement of lipid level were
performed in less than 1/3 of the cohort and the prescription of car-
diovascular medications was less than 50 % or lower for most drugs
across all calendar years. Encouragingly the rates of current smoking
decreased over time (P \ 0.05).
Conclusions: Patients who initiate dialysis therapy in the Midwest
Region have substantial cardiovascular comorbidity that is similar to
US cohorts. The management of known cardiovascular disease is less
than optimal with low rates of lipid testing and cardiovascular med-
ication use. Substantial opportunities exist to improve modifiable
practice patterns in cardiovascular disease management.
64. Vortex Formation Time in the Assessment
of Patients with Newly Diagnosed Haemochromatosis
1Byrne D, 1Almuntaser I, 1Walsh J, 2Ellis L, 1King G1, 2Norris S,
1Murphy RT
1St James’s Hospital, Dublin, Ireland; 2Gastroenterology, St James’s
Hospital, Dublin, Ireland
Background: Vortex formation time (VFT) is an index of the optimal
conditions for vortex formation. In clinical Haemochromatosis (HC),
subtle inefficient propagation of blood through the left ventricle (LV)
may result from myocardial iron deposition, but accurate measures of
response to treatment are lacking. We assessed echocardiographic-
derived vortex formation time (VFT) in control subjects and patients
with newly diagnosed HC.
Methods: Transthoracic echocardiography was performed in 20
normal subjects (mean age 49.19 ± 2.5) and in 20 patients who have
early HC (mean age 50.66 ± 2.4) with elevated ferritin levels
(953.8 ± 114.5). Conventional parameters and tissue Doppler (TD)
indices were measured. VFTa was obtained using the formula:
4 9 (1 - b)/p 9 a3 9 LVEF, where b is the fraction of total trans-
mitral diastolic stroke volume contributed by atrial contraction
(assessed by time velocity integral of the mitral E- and A-waves) and
a is the biplane end-diastolic volume (EDV)1/3 divided by mitral
annular diameter during early diastole.
Results: The VFT was increased in HH subjects (3.49 ± 0.21)
compared to controls (2.55 ± 0.21) (P = 0.0037). There was no
difference in age, gender, body surface area (P = 0.89). The TD E’
early diastolic myocardial velocities was decreased in HH
(13.39 ± 0.68) compared to controls (15.87 ± 0.67) (P = 0.0139).
Significant correlation was observed between VFT and TDE’ (R = -
0.48 & P = 0.0012). Post venesection VFT will be monitored as a
measure of response to treatment.
Conclusion: VFT is a dimensionless index, incorporating LV dia-
stolic parameters and may provide a useful parameter for the ongoing
assessment of HC patients following venesection.
65. Hospitalisation for Heart Failure: Are We Getting
to the Heart of the Matter?
Sugrue A, Havelin A
University College Hospital, Galway, Ireland
Background: In 2002 over 80,000 people in Ireland were believed to
have heart failure. Greater technology, longevity and understanding
of heart failure pathogenesis will see a rise to a approximately 10,000
new cases per year. Heart failure admissions accounts for almost 1 %
of the health care budget in Ireland. A need to understand the epi-
demiological data in relation to admissions for heart failure plays an
important part in planning of distribution of heart care services. It also
enables to determine the impact of health care programs and policy
implemented.
Aim: To analyse the trends in hospitalisations for heart failure in
Ireland by examination of the number of admissions and length of
stay.
Methods: Data (anonymised) was obtained through the Eurostat
database covering ICD codes for heart failure (I50).
Results: From 2002–2010 there was a total of 51,541 admissions for
heart failure, 28,207 of these were males, 23,334 females. The pop-
ulation over the age of 65 made up a large majority of these
admissions 44,849. The age standardisation hospitalisation rates
decreased from 157.5 to 127.2 per 100,000, a relative decrease of
19.2 %. Males showed a similar decline from 173.4 to 142.6 per
100,000, 18 % reduction. Females showed the greatest reduction
141.8 to 112.1 per 100,000 (21 %). In terms of length of stay there
was a mild increase from 12.0 to 12.4 (3 %). The greatest reduction in
LOS was in the 60–70 year old group from 11.4 days to 9.75 days.
Conclusion: The implementation of national policy and development
of heart failure units has seen a significant reduction in the number of
admissions of heart failure. There has been some reduction in length
of stay, and future research should focus on the potential to improve
this.
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